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This paper describes an individual who was diagnosed with obsessive-compulsive disorder (OCD) and body dysmorphic
disorder (BDD) at age 17 when education was discontinued. By age 19, he was housebound without social contacts except for
parents. Adequate trials of three selective serotonin reuptake inhibitors, two with atypical neuroleptics, were ineﬀective. Major
exacerbations following ear infections involving Group A β-hemolytic streptococcus at ages 19 and 20 led to intravenous immune
globulin therapy, which was also ineﬀective. At age 22, another severe exacerbation followed antibiotic treatment for H. pylori.
This led to a hypothesis that postulates deﬁcient signal transduction by the N-methyl-D-aspartate receptor (NMDAR). Treatment
with glycine, an NMDAR coagonist, over 5 years led to robust reduction of OCD/BDD signs and symptoms except for partial
relapses during treatment cessation. Education and social life were resumed and evidence suggests improved cognition. Our
ﬁndings motivate further study of glycine treatment of OCD and BDD.
Copyright © 2009 W. Louis Cleveland et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Obsessive Compulsive Disorder (OCD) is an illness that
is characterized by recurrent obsessions and compulsions
that cause marked distress and impairment [1]. It has a
lifetime prevalence of 2-3% and is the fourth most prevalent
psychiatric disorder [2]. Estimates suggest that it is the
tenth leading cause of disability in the world [3]. Up to
30–40% of patients fail to respond signiﬁcantly to current
treatments and those who do respond often experience only
partial remissions [4, 5]. Patients who fail to respond to
two serotonin reuptake inhibitors (SSRIs) are considered
“refractory” [6]. Refractory OCD is regarded as an especially
refractory disorder [7, 8] with severe cases being among
the few psychiatric disorders that continue to be treated by
irreversible procedures such surgical interventions, gamma
knifeablation,anddeep-brainstimulationwithpermanently
implanted electrodes [9–11]. Given the nature of these treat-
ments,thereisanurgentneedforeﬀectivepharmacotherapy.
The etiology of OCD is unknown. However, studies
of clomipramine and desipramine revealed eﬃcacy only
for clomipramine [12, 13]. Since clomipramine has SSRI
activity [13], it has been suggested that abnormalities of
the serotonin system play a causal role in OCD. Although
SSRIsremainﬁrst-linetreatmentforOCDandattemptshave
been made to associate polymorphisms in serotonin-related
genes with OCD, no speciﬁc abnormality of the serotonin
system has been deﬁnitively identiﬁed as a cause of OCD.
The role of the dopamine system has also been considered
andSSRIshavebeenaugmentedwithneuroleptics,including
atypical neuroleptics [4]. However, no speciﬁc abnormality
of the dopamine system in OCD has been ﬁrmly identiﬁed.
Recently, abnormal glutamatergic neurotransmission has
also been considered as a basis for OCD.2 Neural Plasticity
In a theoretical analysis, Carlsson concluded that OCD
and attention deﬁcit hyperactivity disorder (ADHD) are
antithetical with regard to phenomenology and with regard
to prefrontal glutamatergic neurotransmission, with OCD
being “hyperglutamatergic” and ADHD being “hypogluta-
matergic” [14]. An experimental study using single-voxel
proton magnetic resonance spectroscopy found that the
combined glutamate/glutamine peak (GLX) in the anterior
cingulate cortex is reduced in OCD [15]. Another study
suggested that sequence variations in the 3 -untranslated
region of the gene for the NMDAR-2B subunit (GRIN2B)a r e
associated with OCD [16]. More recently, polymorphisms in
the gene for the glutamate transporter (SLC1A1)h a v eb e e n
associated with OCD in two studies [17, 18]. Taken together,
these ﬁndings raise interest in abnormal glutamate neuro-
transmission as an aspect of OCD, but much work needs to
be done to clarify the reproducibility of the associations and
the functional signiﬁcance of the polymorphisms.
T h e r a p e u t i ca p p r o a c h e st oO C Dh a v ea l s ob e e n
attempted with reagents that modify glutamate neuro-
transmission. For example, riluzole [19]w a su s e dt o
augment pre-existing medication in an open 12-week trial
with 12 treatment-resistant subjects. N-acetylcysteine [20]
has been used with reported success to augment an SSRI
in a case of refractory OCD. Topiramate augmentation of
paroxetine has been reported to be beneﬁcial in one case
of refractory OCD [21]; whereas it appeared to cause OCD
in two other cases [22, 23]. All of the foregoing trials are
confounded by the use of more than one psychotropic
reagent. To our knowledge, there are no reports of
modulators of glutamate neurotransmission being used
alone in a sustained fashion to treat OCD.
In contrast to approaches based on neurotransmitters,
S w e d oa n dc o w o r k e r sh a v ep r o p o s e dt h a tas u b t y p eo fO C D
is the result of an antigen-speciﬁc autoimmune response that
is stimulated by GABHS infection [24–26]. This diagnostic
subtype is referred to as (pediatric autoimmune disorders
associated with strep) PANDAS and may include OCD or
Tourette syndrome as well as other comorbidities. Predic-
tions of the PANDAS hypothesis for therapy have been tested
in trials with IVIG and plasma exchange. Positive ﬁndings
were initially reported [25, 26]. However, in the nine years
following the placebo-controlled trial [26], these treatments
do not appear to have become widely used, raising questions
about the generality of the initial ﬁndings.
Body Dysmorphic Disorder (BDD) is an illness of
unknown etiology that is characterized by excessive preoc-
cupation with an imagined or minor defect in body appear-
ance [27]. The preoccupation creates substantial distress or
impairment. BDD is often a severe disorder and has been
associated with an elevated suicide rate [28]. In a nationwide
study in Germany, BDD was found to have a current
prevalenceof1.7%[28].BDDisapoorlystudieddisorderfor
which available treatments are frequently inadequate, with
27–47% failing to respond to adequate trials of SSRIs [29]. It
is of interest that antipsychotics, either as monotherapy or as
SSRIaugmenters,arereportedtobeineﬀectiveforBDD[29].
BDD is not unusual as a comorbidity of OCD, occurring
in 12% of cases [30]. The combination of OCD and BDD
is usually found to exhibit more impairment and a poorer
prognosis than OCD alone [30–32].
In this paper, we describe a case of refractory OCD and
BDD in which infection-triggered exacerbations appear to
have played a prominent role. A serendipitous observation
of an exacerbation that followed treatment with a commonly
used antibiotic has led to an hypothesis that postulates a
deﬁciency in the NMDAR signal transduction cascade. This
hypothesis points to a new direction of research on the
molecular basis of OCD and BDD and makes the clear
prediction that enhancement of NMDAR neurotransmission
should provide amelioration of symptoms. In this paper, we
present the observations from a ﬁve-year period in which
glycine,anNMDARcoagonist,wasusedasthesoletreatment
of previously refractory OCD and BDD.
2. Methods
This study has been conducted under a protocol approved
by the Institutional Review Board of the Institute for Health
Sciences of St. Luke’s-Roosevelt Hospital Center. Written
informed consent under the aegis of this protocol has been
obtained for the publication of the historical information in
thispaper.Inaddition,thesubject(referredtoas“O”inwhat
follows) has read this paper and has given additional written
informed consent for the publication of his case details.
To protect subject identity, precise values of clinical tests
with numerical results, which could be used as identiﬁers,
have been replaced with approximate values indicated by
“∼”. Diﬀerences between modiﬁed and actual values are
suﬃciently small to be of no scientiﬁc signiﬁcance.
A key resource for this naturalistic study has been
a family-compiled archive that includes behavioral and
medical information from birth to the present time. This
information includes extensive written and recorded oral
diary entries by O’s father as well as written entries by O.
In addition to blood test results, there are either reports
or copies of charts from specialists and copies of charts
of primary care physicians (from birth to the present).
Photocopies of some prescriptions and pharmacy records
covering the period when psychotropic medications were
used are also available. In addition, tablet containers for
psychotropic medications and some other medications have
been retained as a primary record of medication prescribed.
Detailedrecordsofcompliancemonitoringarealsoavailable.
Academic reports from kindergarten to the present, many
examples of school work done by O, records of formal cog-
nitive testing at ages 7 and 30, and results on standardized,
US academic tests are also available. A valuable feature of O’s
archive is the existence of redundant information on many
issues of critical importance. This has made it possible to
identify and resolve discrepancies.
An important category of information in the archive is
objective information from individuals or organizations that
are unconnected with this study (referred to in what follows
as “third-party” objective information). This category is free
of concerns about bias arising from the fact that the subject,
the subject’s parents, and the investigators were not blinded
inrelationtoglycinetreatment.ThiscategoryofinformationNeural Plasticity 3
has been essential to establish the claim that there was major
and persistent impairment before glycine treatment and
substantial reduction of impairment following treatment. It
has also been essential for establishing the occurrence of a
substantial relapse in a period of nontreatment.
The archive also contains recorded observations of
objective phenomena made by the subject or his parents.
O’s father reports that he has given emphasis to objective
and qualitative indications of changes in behavior that were
sustained over time. This information has been evaluated
for its internal consistency and its consistency with third-
party objective information. Subjective information (e.g.,
O’s symptom reports and parental judgments) has also
been evaluated for internal consistency and consistency with
third-party objective information.
In cases where observations were recorded or recalled
from memory at substantial time intervals after events
occurred, this is explicitly indicated in the text. Moreover,
serial interviews have been used to check the consistency
of such recollections. A major eﬀort has also been made
to determine when observations could represent concept-
driven perceptions or represent concept-driven selection of
data. Examples of relevance to the conclusions of this paper
are discussed in the text.
General medical history, radiological ﬁndings, and
descriptions of OCD- and BDD-related behavior are
included in an appendix, since this information may be
useful for future deﬁnitions of glycine-responsive subtypes
of OCD and BDD and as constraints on molecular mod-
els. Additional documentary material on methods and
behavioral phenomena is at www.informaticpsychiatry.org/
glycine.
3. Results
3.1. Time Course of Psychiatric Illness from Early Childhood to
GlycineTreatment. O’sparentsrecalltheirchildashappyand
contented for the ﬁrst two years of his life. However, at age 2,
theyrecallthesuddeneruptionofseparationanxietythatwas
much more intense than what they saw in other children in
their social group. The prodrome of O’s illness became more
clearly apparent at age 7 when he received psychotherapy
from a psychiatrist whose chart noted “anxiety enormous.”
At this time, learning diﬃc u l t i e si ns c h o o lp r o m p t e da
request for cognitive testing, which revealed evidence for
mild cognitive deﬁcits. With improved school performance
and social adjustment, psychotherapy was discontinued after
one year.
As an adult, after developing an understanding of his ill-
ness,Ohasrecalledwall-touchingritualsasearlyasage9,but
these were not noticed by parents. O’s parents believe they
can recall several very mild examples of obsessive mentation
that involved reassurance rituals as early as age 9. At age
14, they clearly recall a wall-touching ritual. Although they
report that they were unaware of the concept of obsessive-
compulsive disorder at that time, they regarded this behavior
as abnormal and initiated a psychiatric consult. However,
parental records and the psychiatrist’s chart indicate that a
diagnosis of OCD was not obtained at this time.
Themildprodromeintheprepubertalyearswasfollowed
by frank illness that emerged rather abruptly at age 15
when school attendance was disrupted. After attending ∼1/2
of ninth grade, O and his parents report that he refused
to attend school any longer after developing the fear that
students in the school had weapons. However, the presence
of weapons was denied by school oﬃcials. This fear of crime
waslaterfoundtobeassociatedwithapowerfulline-crossing
obsession that involved the fear that individuals likely to
commit crimes were entering into his neighborhood. This
obsession was associated with reassurance rituals referred to
as “talk-throughs” (Appendix A.1.1). At this time, cognitive
behavior therapy was attempted by a psychologist who is
reported by O’s parents to have found a mirror phobia and
mild anxiety. No diagnosis of OCD or BDD was given.
Attempts by the psychologist to treat the putative mirror
phobia with a desensitization protocol are reported to have
failed, and both O and his parents currently consider that
“working on the mirror” intensiﬁed rather than reduced
the mentation and behavior that was later diagnosed as
BDD. With the endorsement of the psychologist, O was
sent to boarding school where fears of ugliness and the
“mirror phobia” are reported by both O and his parents to
have intensiﬁed. When O returned home on vacation, he
refused to return to school because of the “mirror problem.”
Additional eﬀorts by the psychologist to achieve mirror
desensitizationwereagainunsuccessfulandledtopsychiatric
consultations that resulted in diagnoses of OCD and BDD at
age 17.
Manifestations of BDD before age 15 are not recalled by
O’s parents. O currently recalls being mildly disturbed by his
seventh grade class picture (age 13). In any case, available
evidence suggests that BDD was preceded by obsessive-
compulsive behaviors, which were preceded by cognition
deﬁcits.
In response to the diagnoses of OCD and BDD, SSRI
therapy was prescribed. A trial of ﬂuoxetine (40–80mg/day,
134 days) was ineﬀective and was followed by a long trial
of ﬂuvoxamine (200–300mg/day, 251 days). A signiﬁcant
response with the latter was also not obtained. A second
opinion from a research psychiatrist specializing in anxiety
disorders conﬁrmed the diagnoses of OCD and BDD and
recommended risperidone as an adjunct to ﬂuvoxamine.
At age 19, during the trial of ﬂuvoxamine (300mg/day) +
risperidone (2mg/day), a severe exacerbation occurred that
involved intensiﬁcation of pre-existing symptoms and the
emergence of terrifying, violent imagery, a symptom which
had not been reported before. After full completion of the
recommended 30-day risperidone trial, diary records indi-
cate a decision by O’s parents to suspend pharmacotherapy
on the basis of their concern that this exacerbation was a
reaction to the medication. Psychotherapy was subsequently
initiated with a diﬀerent psychiatrist and was continued for
about nine months. Following the age-19 exacerbation, O is
reported to have become largely housebound as a result of
the line-crossing obsession associated with a fear of crime
(Appendix A.1.1). He left his home rarely and only with
parental escort. The addition of BDD by proxy to pre-
existing self-related BDD also occurred at this time. BDD4 Neural Plasticity
by proxy involved O’s fear/belief that his parents were ugly
and that he looked like them (Appendix A.1.2). Also present
were somatic/cognitive preoccupations that were very mild
in relation to other symptoms (Appendices A.1.3 and A.1.4).
One year after the age-19 exacerbation, there was another
exacerbation similar to the previous one in its severity and in
the emergence of terrifying violent imagery. However, in this
exacerbation, no psychotropic medication had been taken in
the past nine months.
After further deterioration following the age-20 exacer-
bation, another OCD expert was consulted. The diagnoses of
OCD and BDD were conﬁrmed. Paroxetine (50–70mg/day)
and olanzapine (5mg/day) were prescribed and O was
referred to another psychiatrist for behavior therapy and
weekly monitoring. The latter soon added clonazepam (0.5–
4.0mg/day). In spite of an initial, apparent improvement
that permitted O to go for short, unescorted walks in his
neighborhood during a three-week period, a clear deteriora-
tion was apparent after 3.5 months, leading the psychiatrist
to terminate olanzapine and to continue paroxetine at 60–
70mg/day foranother 9months. Againno improvement was
perceived.
In response to the failure to make progress with
established pharmacotherapy, O and his family began to
search for newly emerging treatments. When O was 21,
they became aware of the PANDAS concept of Swedo
and coworkers [24–26]. Consultation with O’s pediatrician
revealed that two severe cases of bilateral ear infections
with β-hemolytic-positive throat cultures had occurred
approximately 1-2 months before the peaks of the age-
19 and age-20 exacerbations (β-hemolytic-positive throat
cultures are ∼50% probable GABHS infection in temper-
ate climates, J.B. Zabriskie, personal communication). O’s
father’s diary contains a detailed description of the age-
19 exacerbation, which began as soon as the infection
cleared. Seeing their son’s further deterioration, O’s parents
agreed to augmentation of ﬂuvoxamine with an atypical
neuroleptic. O’s father emphasizes that at that time he had
no knowledge of the PANDAS concept and therefore did
not associate the deterioration with the β-hemolytic-positive
infection that was discovered retrospectively two years
later.
The retrospective discovery at age 21 that probable
GABHS infections preceded the age-19 and age-20 exac-
erbations led to consultations with a rheumatologist. In
response to a report that IVIG treatment was eﬀective with
PANDAS [26], IVIG therapy was initiated. Paroxetine was
tapered from 60mg/day to zero and overlapped IVIG for
only two months. IVIG therapy was initiated at 160 grams
for the ﬁrst month and 80 grams/month for an additional
17 months. Although there was an apparent behavioral
improvement after the ﬁrst infusion, this improvement was
not sustained and IVIG was eventually terminated for lack
of eﬃcacy. About 3 months after the IVIG trial began,
500mg/day of amoxicillin was added as a prophylaxis against
GABHS. O’s parents report no obvious beneﬁt, and also no
obvious deterioration, from amoxicillin prophylaxis, which
was terminated after about 6 months to permit initiation of
ad i ﬀerent antibiotic regimen to remove H. pylori.
Nine months into the IVIG treatment, removal of H.
pylori using a combination of clarithromycin (1000mg/day),
amoxicillin(1500mg/day),andlansoprazole(30mg/day)for
12 days was associated with a severe exacerbation of existing
obsessions and compulsions and emergence of highly dis-
tressfulviolentimagery.Episodesofhighlydisturbingviolent
imagery are reported to be extremely distinctive, occurring
only three times in O’s life, namely in this exacerbation at age
22 and in the two major exacerbations at ages 19 and 20 that
followed severe bilateral ear infections. Another distinctive
featureofthisexacerbationwasamuchstrongerpresentation
of ritualistic behaviors than ever seen before, either during
baseline illness or during previous exacerbations. O’s father’s
diary indicates that the main ritual was a prayer ritual that
wasperformedformanyhours a day, leading initially to knee
erosions that were followed by calluses. Another distinctive
feature of this exacerbation is its similarity to the previous
ones in which there was a gradual rise in symptoms over
a period of approximately 1-2 months. Before, during, and
after the antibiotic treatment, measurements of streptolysin
O titers were negative. After the peak of the exacerbation,
recordsindicate that theprayerritualgraduallydeclined over
a period of approximately 12 months to generate a new
baseline in which ritualistic behaviors are reported to have
been increased relative to pre-exacerbation levels.
After the termination of IVIG treatment, O’s parents
report that they decided to support their son at home
on their own until a new treatment was developed. While
waiting for the development of new treatments (from age
23 to 25), O and his parents tried on their own initiative
and in consultation with physicians various nutraceutical
treatments, (e.g., [33, 34]) that had been developed for other
illnesses that are sometimes associated with OCD, such as
Huntington’s disease [35]. However, none showed eﬃcacy.
Theglycinetrialdescribedbelowrepresentedanotheroftheir
eﬀorts involving the use of a nutraceutical.
3.2. Stability of Psychiatric Diagnoses. The diagnoses of OCD
and BDD that were given at age 17 by a psychiatrist
were subsequently conﬁrmed by several other psychiatrists,
including two OCD specialists. No signs or symptoms of
other major psychiatric illnesses have been noted by the
multiple psychiatrists who have examined O. There is no
evidence of substance misuse, as noted in General Medical
History (Appendix A.2) .I nO ’ sc o n t i n u o u sa n dg e n e r a l l y
increasingillness,individualsignsandsymptomshavevaried
in intensity over time. However, the basic spectrum of
signs and symptoms appears to have been unchanged since
the emergence of frank illness at age 15, suggesting stable
diagnoses from age 17 to age 30.
3.3. Development of Hypo-NMDAR Signal Transduction
Hypothesis. At the time of the exacerbation that followed H.
pylori eradication, it was considered that the exacerbation
could have been due to one or more of the three agents
used to achieve eradication (amoxicillin, lanzoprazole, clar-
ithromycin). Clear precedents for psychiatric sequelae of
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at that time. More recent literature suggests that beta-
lactams can modulate glutamate neurotransmission but that
doses substantially above the therapeutic range appear to be
required [36]. Consistent with this ﬁnding is the observation
that O has taken amoxicillin on multiple occasions before
andaftertheexacerbationwithoutadverseeﬀects.Incontrast
to amoxicillin and lanzoprazole, there were reports describ-
ing substantial CNS and psychiatric sequelae from macrolide
antibiotics, including clarithromycin. However, a majority of
reports on psychiatric sequelae from clarithromycin claimed
remission immediately after cessation of treatment. In O’s
case, the exacerbation continued to increase over a period of
approximately 2 months after the 12-day treatment period.
Consequently, the role of clarithromycin was discounted
until a reanalysis three years later in 2002.
In 2002, one of us (W. L. Cleveland) became aware
of studies of phencyclidine’s eﬀects on patients with
medication-controlled schizophrenia. A remarkable ﬁnding
is that a subpopulation of these patients can exhibit a
prolonged exacerbation following a single, brief exposure to
the drug. This observation was speciﬁc for phencyclidine, an
NMDAR inhibitor. Drugs interacting with other receptors,
such as LSD, failed to exhibit protracted exacerbations
(see [37, 38] and references therein). The similarity of the
protracted kinetics of the phencyclidine response to the
kinetics of the antibiotic-induced exacerbation seen in O
led to a literature search for evidence that clarithromycin
could inﬂuence NMDAR neurotransmission. A paper by
Manev et al. provided evidence that clarithromycin could
inhibit cell death from glutamate-induced excitotoxic injury
in cultures of human cerebellar neurons [39]. Protection was
against NMDA-mediated but not kainate-mediated excitoxi-
city.ActivationoftheNMDARasindicatedbycalciuminﬂux
was not inhibited, suggesting that clarithromycin (and the
other macrolides studied) inhibited a downstream aspect of
the NMDAR signal transduction (NMDAR-ST) cascade.
The physiological relevance of the data of Manev et
al. was also analyzed. The concentrations used in their in
vitro studies were in the range of 100μM. The literature
indicates that clarithromycin can reach comparably high
concentrations in tissues and cells, with concentration
increasing in proportion to the duration of treatment [40].
Moreover, access of clarithromycin and its main, active
metabolite, 14-OH-clarithromycin, to the brain is suggested
by the observation that clarithromycin is useful in the
treatmentofcentralnervoussystemtoxoplasmosisinfections
[41, 42]. It should be noted that low concentrations of
macrolides in cerebrospinal ﬂuid (CSF) are an indication
of a marked tendency for macrolides to accumulate in cells
rather than poor access to the brain. For example, a study
of azithromycin found ∼3μg/g in brain tissue, whereas in
C S Fi tw a sb a r e l yd e t e c t a b l e[ 43]. The macrolide aﬃnity
for cells is also seen in a comparison of clarithromycin and
azithromycin, which reached levels of 940μM and 520μM,
respectively, in alveolar macrophages [40].
The above considerations led to the hypothesis that
clarithromycin induced an exacerbation by inhibition of
a downstream aspect of the NMDAR-ST cascade. More-
over, it seemed plausible that this inhibition modulated,
either directly or indirectly, the intrinsic defect responsible
for baseline symptoms. An immediate prediction of this
hypothesis is that an NMDAR agonist (or coagonist) would
lead to symptom improvement. This prediction motivated
consideration of the high-dose glycine treatment developed
for schizophrenia, which has been used with apparent safety
as an adjunct to other medication in trials beginning in 1988
[44, 45].
After consultation with physicians, O decided to initiate
a trial of glycine at 0.8grams/kilogram of body weight/day,
the dose used with apparent safety in schizophrenia trials
[45]. The initial response to glycine was monitored in
relation to major life disruptions (see below) and in relation
to the speciﬁc signs and symptoms of preglycine illness
(Appendix A.1).
3.4. Major Life Disruptions
School. A sign of major impairment is no attendance of
high school after failing to complete tenth grade. An attempt
to continue O’s education with one-on-one tutoring was
discontinued six months after stopping regular school. O,
however, did make sporadic attempts to study at home. This
led to an unsuccessful attempt to take GED examination (for
high school equivalency diploma) at age 25, several months
before initiation of glycine treatment. Records indicate that
when O arrived at the test site, he refused to enter, giving
an explanation related to his line-crossing obsession. At this
time, he also refused to handle photo-identiﬁcation for entry
into the test site. Thus, in the 8-year period preceding glycine
treatment (age 17 to age 25), there was no regular school or
formal tutoring.
Social Life. The diary maintained by O’s father indicates
that by age 19, O had become housebound except for
doctor visits, visits to his father’s place of work, and rare
visits to an art museum, all of which required his father’s
escort and door-to-door taxi travel along routes that were
perseveratively selected by O because of the fear that his line-
crossing obsession would be triggered by people he might
see on alternate routes. At age 21, there was a brief period of
about 3 weeks duration, during treatment with paroxetine +
olanzapine,inwhichOwentforshort,unaccompaniedwalks
in his neighborhood. Otherwise, records indicate that O was
housebound in the six-year preglycine period that followed
the age-19 exacerbation. His only in-person social contacts
were with his parents at home. There were no other social
contacts except for telephone contact with a grandmother in
another city.
Behavior at Home. O’s disorganized lifestyle is reported
to have created disarray in his home that prevented O’s
parents from bringing guests to their home for at least
seven years preceding glycine treatment. There was also poor
personal hygiene and grooming. Most of O’s attention was
on television and the internet. His sleep cycle was frequently
inverted. O’s made some eﬀort to do school work, but he
was generally resistive to parental tutoring. Any attempt to6 Neural Plasticity
discuss academics was thwarted by the tendency to discuss
an obsession.
The last exacerbation in the preglycine period occurred
3 years before initiation of glycine treatment. As noted
previously, the decline of this exacerbation over about one
year led to a baseline in which ritualistic behaviors were
increased relative to the pre-exacerbation baseline. This new
baseline remained stable in the two years preceding the
initiation of glycine treatment. It was against this stable
baseline of clear and substantial impairment involving the
above life disruptions that the response to glycine treatment
was initially detected.
3.5. Response to Glycine Therapy. In this 5-year study of
glycine treatment, decisions to start and stop glycine treat-
ment were made by O in consultation with physicians.
Table 1 lists observation periods and the corresponding
glycine doses. Target doses varied from 50 to 66g/day (0.6–
0.8 grams of glycine per kilogram of body weight). As
an indication of compliance, the percentages of total days
for various dose ranges are given. Average daily doses for
observation periods are also given. Tables 2 and 3 summarize
behavioral and cognitive changes, respectively.
3.5.1. Observation Period 1 (on Glycine for 203 Days, 1–203).
Glycine treatment was typically initiated by increasing the
dose over 12 days from 10g per day to the target dose. In
Observation Period 1 (OP1), the full dose was initially taken
t.i.d.,but,forreasonsofconvenience,wassubsequentlytaken
b.i.d. The daily target dose was varied from 50 to 66g/day in
this period. Glycine was abruptly terminated on day 204 due
to an upper respiratory infection with high fever.
O’sfather’sdiaryindicatesthattheﬁrstimprovementwas
seen 23 days after reaching target dose on Day 34-OP1(34)
(Day 34 of Observation Period 1 (Day 34 of Study)). For the
ﬁrst time in 5 years, O left his apartment building without
parental escort and went for a short walk in front of his
building. Soon after this, he began daily attendance a nearby
library where he prepared for the high school equivalency
exam (General Education Development (GED) test of the
American Council of Education). This is reported to have
been done on a 9AM to 5PM weekday schedule without
parental escort.
The GED exam was passed on Day 145-OP1(145) in
the standard time period. Oﬃcial scores on the ﬁve GED
subtests ranged from the 67th to the 99th percentile on scales
normalized to scores of graduating high school seniors in the
US.
Reduced intolerance to mirrors is supported by a sus-
tained resumption of barbershop haircuts after approxi-
mately ﬁve months of glycine treatment. O was escorted to
barbershops by his father, who reports that he observed no
obvious distress over mirrors. Haircuts had been given at
home for the past seven years.
Six months after initiation of glycine treatment, O was
encouraged to study in a diﬀerent library on the campus of
a university near his home. Reaching the campus required
paternal escort and crossing a busy street that had previously
been avoided due to the line-crossing obsession. Entry
requiredthepresentationofaphoto-identiﬁcationcard.This
was an improvement over the preglycine period in which O
insisted that his father handle his photo-identiﬁcation.
O’sparentsconsiderthatthepartialtoleranceofthestreet
and campus indicated a signiﬁcant and further reduction of
the line-crossing obsession. At this time, O’s father’s diary
indicates that talk-throughs, which had been daily before
glycine treatment, had become infrequent. The willingness
to handle a photo-identiﬁcation card is taken as a sign of a
reduction of BDD.
Although substantial illness remained, the data for OP1
suggest steady and signiﬁcant progress during the ﬁrst 200
days of glycine treatment.
3.5.2. Observation Period 2 (oﬀ Glycine for 41 Days, 204–244).
On Day 1-OP2(204), O developed an upper respiratory
infection with fever as high as 104.2◦F (oral, Hg thermome-
ter). A commercial lateral ﬂow immunoassay for GABHS
antigens (One-Step ClearVue, Quidel, San Diego, CA) was
negative. However, a course of augmentin was prescribed.
Since this fever was thought to be unusually high in relation
toO’spriorhistory,Oandhisparentsbecameconcernedthat
it could be due to glycine. This led to the discontinuation of
glycine treatment for 40 days.
Detailed notes in O’s father’s diary suggest a gradually
rising exacerbation following the infection. On Day 21-
OP2(224), the line-crossing obsession was activated on
the way home from the library, leading to the ﬁrst talk-
through in quite sometime. The next day, it took an hour
of parental urging to get O to leave his home. O reported the
emergence of a hand-washing ritual driven by fear of harm.
Talk-throughs again became a daily occurrence. O’s parents
describe an unequivocal but not major loss of prior gains.
Although unequivocal, they described this exacerbation as
distinctlylessintensethanthemajorexacerbationsatages19,
20, and 22. Most notably, it did not involve terrifying violent
imagery.
By the time of this exacerbation, both O and his parents
were aware of the concept that exacerbations could result
from infections. Therefore, there is the possibility that the
exacerbation described for this period reﬂects concept-
driven perceptions or selection of data. However, O’s father
notes that, at that time, they expected exacerbations only
from GABHS infections, since the two previous infection-
associated exacerbations were associated with positive throat
cultures.Therefore,asaresultofthenegativetestforGABHS
done at the beginning of the infection in the oﬃce of
O’s primary care physician, an exacerbation is described as
unexpected.
3.5.3. Observation Period 3 (on Glycine for 127 Days, 245–
371). In response to the deterioration seen in OP2, O and
his family decided to resume glycine treatment on Day
1-OP3(245). After 5 days at 25g/day, glycine was again
terminated because of another infection with chills and
vomiting and a fever of 102.4◦F. No antibiotic was taken.
Glycine was again resumed at full dose (50g/day) on DayNeural Plasticity 7
Table 1: Glycine consumption in the ten observation periods∗.
Observation
Period
Start Day Stop Day No. Days Average %Days %Days %Days %Days %Days %Days
Gly/daygm 50–66gm 40–49gm 30–39gm 20–29gm 10–19gm 0gm
1 1 203 203 44.6 50.7 23.6 1.0 20.2 1.5 3.0
2 204 244 41 0 00000 100
3 245 371 127 36.0 55.9 0.8 1.6 28.3 0 13.4
4 372 411 40 0 00000 100
5 412 548 137 33.3 34.3 20.4 5.8 19.7 1.5 18.2
6 549 768 220 0 0 1.4 2.3 3.6 1.4 91.4
7 769 1022 254 37.5 50.8 2.8 3.1 27.2 1.6 14.6
8 1023 1068 46 0 00000 100
9 1069 1400 332 43.1 59.0 4.2 0.6 27.1 2.7 6.3
10 1401 1941 541 0 00000 100
∗Amounts indicated are amounts weighed. Amounts taken are less due to the tendency of glycine to settle and leave a residue in the drinking glass.
13-OP3(257). On Day 21-OP3(265), O reported a reduction
in rituals. Fewer rituals and fewer complaints related to the
line-crossing obsession were noted on Day 29-OP3(273).
Other observations suggest a rapid recovery of lost gains.
On Day 31-OP3(275), O was escorted only to the edge of
the campus, walking to the library by himself. The trend to
improvement is further suggested by the fact that by Day 85-
OP3(329), O began freely exploring the entire campus. On
Day91-OP3(335),hebeganworkingwithatutor(otherthan
his parents) for the ﬁrst time in 9 years. Records indicate
that talk-throughs again became rare. Increased tolerance
of his mother’s face is suggested by attendance with her at
movies and restaurants and acceptance of her help with SAT
preparation.
Third-party records indicate that a major activity during
this period was a preparatory course for the SAT, a reasoning
testofTheCollegeBoardrequiredforadmissionbymanyUS
colleges.Courseattendanceinvolvedclassroomparticipation
and practice tests under conditions simulating oﬃcial test
conditions. O’s tolerance of a classroom with many students
suggestsareductionofBDD-relatedsocialdiscomfort.Travel
to the course site was by taxi with parental escort, often O’s
mother. Moreover, the course site was on a street that was
avoided in the preglycine period due to the line-crossing
obsession.
Third-party course records indicate that O’s math scores
in the practice tests increased by 100 points and his verbal
scores by 60 points. According to The College Board, a
diﬀerence of 60 points is evidence of a true diﬀerence in
ability (“standard error of the diﬀerence”) [46].
Inthisperiod,thearchivelistsadozen“landmark”events
in which O resumed an activity that had been prevented
in the preglycine period. Even though they acknowledge
that substantial illness remained, O’s parents report that
they considered the progress achieved by the end of this
observation period to be a dramatic improvement over
preglycine illness.
3.5.4. Observation Period 4 (oﬀ Glycine for 40 Days, 372–411).
Given that the exacerbation of OP2 was associated with
both an infection with high fever and a cessation of glycine
treatment, it was unclear if glycine cessation contributed to
the exacerbation. Therefore,O and his family decided to stop
glycine treatment during a period without infections. No
signiﬁcant change was observed in this period.
3.5.5. Observation Period 5 (on Glycine for 138 Days, 412–
548). In this period O made his ﬁnal eﬀorts to prepare for
the SAT that was taken on Day 68-OP5(479). Scores on the
actual tests, which were taken in the standard time intervals,
surpassed all practice test scores. His verbal score was in
the 90th percentile and was 60 points higher than the best
practice test and 120 points higher than the ﬁrst practice
test. As noted above, a 60-point increase is statistically
meaningful. His math score was at the 50th percentile and
was 30 points better than the best practice score and 130
points higher than the lowest practice test.
O’simprovedlifestyleathomeledhisparentstorenovate
their home and resume normal family social life for the ﬁrst
time in 8 years. Diary records indicate that he was present for
the ﬁrst visit of a family friend to his home in ﬁve years.
I nt h i so b s e r v a t i o np e r i o d ,Ob e g a nt ow a l kf r e e l yi n
his neighborhood without any escort. This step forward is
among the 10 “landmark” occasions in the archive where
O resumed an activity prevented in preglycine period. Talk-
throughs largely disappeared in this period. Barbershop
haircuts continued.
OP5 is important because it reveals the robustness and
stress-resistance of O’s improvements. On Day 68-OP5(479)
therewastheSAT.Thiswasfollowedbyapplicationtocollege
which required an interview with an admissions oﬃcial on
Day 112-OP5(523). Although the interview is reported to
have gone well, O’s application was rejected on Day 123-
OP5(534). On Day 137-OP5(548) O attended an alternative
collegethatwaslocatedatasitethatwouldhavebeenamajor
line-crossing trigger in the preglycine period. In response to
this sequence of major stressors, O’s father reports that he
saw no loss of gains. Taken together, the data for OP5 suggest
further substantial improvements that were a continuation
of gains seen in OP3.8 Neural Plasticity
3.5.6. Observation Period 6 (oﬀ Glycine for 220 Days, 549–
768). As described in OP2, an upper respiratory infection
with high fever was followed by a behavioral exacerbation.
A concern that glycine might have caused the unusually
high fever led to the decision to stop glycine during the ﬂu
season. The extension beyond the ﬂu season was due to O’s
reluctance, arising from the unknown safety of long-term,
high-dose glycine therapy.
It was at the beginning of this observation period that O
resumed his formal education after not attending school for
an entire decade. As noted above, O was not accepted in the
collegeofhischoice.However,theletterfromtheAdmissions
Oﬃce encouraged reapplication after demonstrating com-
petence at another institution. O thus felt under pressure
to obtain high grades. Two courses, College Algebra and
English, were taken. The archive indicates that O attended all
classes, completed all assignments on time, and received no
special accommodations. He is reported to have tolerated the
stressassociatedwithacademicdeadlines,includingall-night
sessions to complete papers. Academic records document
very high grades that permitted a successful reapplication to
the college of his ﬁrst choice.
In this 4.5-month period of glycine cessation, there
were two indications of a loss of prior gains: a decline in
cognition (see Section 3.5.11) and a mild increase in the
line-crossing obsession. There was also an intensiﬁcation
of somatic/cognitive preoccupations to the point that they
generated (for the ﬁrst time) mild impairment. A notable
feature of OP6, the ﬁrst lengthy (220-day) oﬀ-glycine period
is that the observed, mild relapse in OCD was circumscribed
a n do c c u r r e ds l o w l y .
3.5.7. Observation Period 7 (on Glycine for 254 Days, 769–
1022). The decision to resume glycine is reported to have
been due to multiple considerations. In addition to a general
perception of relapse by O’s parents, there was also a major
concern about the impact of the apparent cognitive decline
seen in OP6 (see Section 3.5.11)o na c a d e m i cp e r f o r m a n c e
in a new college with a more demanding curriculum. While
O’s parents report that they strongly encouraged resumption
of glycine therapy, the ﬁnal decision was left to O as in the
past.
Attendance at the new college began on Day 13-
OP7(781) with O taking two courses. One course proved
to be quite diﬃcult for O. A low grade on the ﬁrst exam
of this course was obtained on Day 40-OP7(808). This is
reported to have generated considerable stress, since O as a
new student with an unusual academic and personal history
was under pressure to demonstrate his ability to handle the
curriculum. O’s father’s diary indicates that there were no
signs of a behavioral relapse from this stressful experience.
O ﬁnished the semester with a respectable grade in the other
course. He is reported to have handed in all assignments on
time and to have attended all classes except for one. Stresses
from academic deadlines, for example, all-night sessions
to complete papers, are reported to have been handled
without any sign of a behavioral deterioration. In the second
semester, academic records show that the same consistently
adequate performance continued with respectable grades.
An important BDD-related gain in this period is O’s
reported resumption of hair combing in front of a mirror.
Although O covered his nose and mouth with one hand,
this maneuver suggests an increased tolerance of mirrors,
since, prior to this period, hair combing was reportedly
done with parental assistance or by manual feeling without
visual feedback. O’s father reports that this maneuver did
not involve any repetitive “working on the mirror,” as hair
combing was done quickly. Barbershop haircuts continued.
Another BDD-related “landmark” event in this observa-
tion period is seen in an entry in O’s father’s diary on Day
34-OP7(802), which indicates that O began to tolerate direct
observation of his father’s face in a sustained manner. Prior
to this, tolerance of direct observation is reported by O to
have occurred but only sporadically. O tolerated his mother’s
face during multiple social events in this period. However,
he continued to maintain that he kept her face in peripheral
vision.
The line-crossing obsession appears to have become
much reduced in this period. O’s father’s diary notes only
a single talk-through dealing with this obsession. The only
obvious remnant of the line-crossing obsession was a partial
restriction of the use of public transportation.
In summary, there were notable gains that involved
coping eﬀectively with a new and challenging academic cur-
riculum, a further reduction in the line-crossing obsession
a n dr e d u c t i o n si ns e l f - r e l a t e dB D Da n dB D Db yp r o x y .
Somatic/cognitive preoccupations appear to have remained
mild without any clear change. Importantly, multiple stress-
ful events did not lead to any obvious loss of behavioral
improvement.
3.5.8. Observation Period 8 (oﬀ Glycine for 46 Days, 1023–
1068). The decision to stop glycine was as alwaysmade by O.
The reasons were not recorded. O’s father reports that he was
not able to detect any consistent trend toward deterioration
or toward improvement.
3.5.9. Observation Period 9 (on Glycine for 331 Days, Days
1069–1400). Eightythreedaysafterglycineresumption(Day
83-OP9(1151),Obeganthethirdsemesterathisnewcollege,
registering for two courses. Academic records indicate that
O obtained the highest possible grade in one course and
next to the highest possible grade in the other course. No
courses were dropped. On Day 216-OP9(1284), the fourth
semester began. As before, two courses were taken and the
same excellent grades were obtained.
Diary entries and email correspondence indicate that
social activities occurred in classes, in student centers, at
social events for students, and at athletic events. All of these
activities, except for in-class socialization, are reported to
have occurred for the ﬁrst time in this semester. On Day 202-
OP9(1270), O went on his ﬁrst date with a girlfriend in 13
years.
Also of interest in OP9 are records indicating a substan-
tial reduction in the signs of BDD by proxy involving O’s
mother’sfaceandin thesignsofBDDinvolving hisownface.
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directly at a mirror image of his face with only his mouth
and the bottom surface of his nose covered. Previously, he
had found it necessary to cover his nose and lower part
of his face. Another indication of reduced BDD intensity
is the occurrence of very few BDD-related talk-throughs in
OP9. O’s father’s diary lists 13 talk-throughs for the entire
47-week period. Only several of these were BDD-related.
Taken together, the above observations suggest signiﬁcant,
additional reduction of BDD during OP9.
As noted above, the line-crossing obsession was consid-
ered by O and his parents to be substantially reduced by the
end of OP7. In OP9, there are indications for the further
reduction of this obsession. Most notably, O is reported to
have begun freely traveling about his city using bus and
subway transportation. This was done either alone or with
peers without restrictions on time or areas traversed. O’s
father’s diary records no talk-throughs regarding the line-
crossing obsession in OP9. As in OP7, there were no signs
of any sensitivity to crime news. Both O and his parents
currently report the complete disappearance of the line-
crossing obsession in OP9.
Somatic/cognitive preoccupations are reported in O’s
father’s diary to have been the subject of most of the thirteen
talk-throughs listed in this 331 day period. O’s parents con-
sider that somatic/cognitive preoccupations became milder
in the ﬁnal parts of OP9. This is supported by the absence
of medical consults for somatic preoccupations in these
periods.
On the basis of the excellent progress in this period,
O and his parents report that glycine treatment would
have been continued had it not been for the occurrence of
unexplained weight loss. OP9 was terminated on Day 332-
OP9(1400) to observe weight ﬂuctuations in the absence of
glycine therapy.
Taken together, the above observations for OP9 suggest
the addition of major gains to those seen in OP7 and prior
treatmentperiods.BytheendofOP9,thesegainsrepresented
a largely complete remission of OCD and a large fractional
reduction in BDD-related impairment relative to preglycine
illness. The reduced impairment reﬂected in the high level
of O’s academic and social activities represented a major
reversal of the life disruptions of preglycine illness.
3.5.10. Observation Period 10 (oﬀ Glycine for 541 Days,
1401–1941). Although, unexplained weight loss initiated
this period, O reports that concerns about the unknown
safety of long-term treatment led him to extend it.
Available evidence for this long oﬀ-glycine period sug-
gests the occurrence of a clear but mild relapse in BDD, a
milder relapse in OCD, and a major relapse in cognition (see
Section 3.5.11).
Clear signs of a relapse can be seen for self-related
BDD. Speciﬁcally, O refused the opportunity to take driving
lessons after the end of the academic semester (Day 372-
OP10(1772)) on the basis that he might see his face in
the mirrors or the windshield of the automobile. The
opportunity to travel to a foreign country was refused
on the grounds that he would not be able to handle his
passport without seeing his picture, although he continued
to handle old photo-identiﬁcation. There was also a return
of a hair-loss preoccupation seen in the preglycine period.
O’s parents consider the above signs to be a clear increase in
BDD intensity and impairment that was modest compared
to pretreatment illness. Additional diary entries suggest an
increase in mother-related BDD by proxy that is reﬂected in
a loss of O’s ability to tolerate his mother’s presence and the
risk of seeing her face.
In OP10, there were no signs of a major return of
the line-crossing obsession. However, two episodes suggest
the beginning of a restriction in mobility. On Day 380-
OP10(1780) O refused to meet his father in an area of
a public park which he had previously visited without
complaint. In a recent interview, O explained that he was
afraid that he would see someone in that location who would
trigger the return of the line-crossing obsession. On Day
362-OP10(1762) O refused to accompany his father to a
restaurantinanareathathadbeenhighlysensitiveinrelation
to the line-crossing obsession in the preglycine period. Diary
records indicate that in OP9, O had gone to restaurants
in the same area with a girlfriend. Some weeks later on
Day 411-OP10(1811), a similar episode occurred. The above
observations suggest a small restriction in mobility resulting
from a mild return of the line-crossing obsession.
On Days 279-OP10(1679), 380-OP10(1780), 388-
OP10(1788), O’s father’s diary contains descriptions of
episodes which suggest a return of concerns about crime-
related news. In a recent interview, O conﬁrmed his father’s
observations.
Somatic/cognitive preoccupations in the ﬁrst part of
OP10 were not greatly changed from the previous observa-
tion period. However, complaints about speech diﬃculties
increased in the last three months of this period, leading to a
consult with a clinical neuropsychologist. The consult failed
toidentifyspeechproblemsbutdididentifymemorydeﬁcits,
which are discussed below in the section on cognition.
This observation period again revealed the slow nature
of the oﬀ-glycine relapse that was seen in OP6, the previous
lengthy oﬀ-glycine period. As before, the relapse of OCD
was modest. BDD exhibited a more unequivocal relapse that
clearlyrepresentedincreasedimpairment,buttherelapsewas
far from the preglycine baseline. Formal cognitive testing
towardtheendofthisperiodrevealedamuchmoredramatic
relapse of the cognitive dimension that is likely to be close to
preglycine baseline (see below).
3.5.11. Eﬀects of Glycine on Cognition. Thirteen days after
ending a glycine treatment period of 138 days (OP5), O
demonstrated rapid learning and retention of new math
concepts in a tutoring session for a math placement exam
given at the time of college enrollment. In this session with
his father, his work was largely free of the types of errors
seen by his father at 14 and also in formal cognitive testing
at age 7. This parental impression was supported by higher
than expected performance on the placement exam. During
the ensuing algebra course, after an additional 21–26 weeks
of glycine cessation, retention diﬃculties and the character-
istic pattern of errors reappeared. These informal observa-
tions suggested the possibility of a cognitive beneﬁt from10 Neural Plasticity
glycine treatment that slowly declined after treatment was
stopped.
The possibility of a cognitive beneﬁt from glycine
treatment was much more strongly suggested by third-party
objective data derived from formal cognitive testing done at
the end of OP10. Toward the end of OP10, O was evaluated
by a neuropsychologist who was blinded to psychiatric and
treatment histories during testing and the preparation of a
preliminary report.
The evaluation indicated that ﬁne motor skills and
speed were within normal limits as were simple attention,
mental manipulation, and sequencing. However, with more
complex tasks requiring manipulation of nonsequential
items, self-monitoring, response inhibition, and set shifting,
performance declined considerably. Visual-perceptual and
visuoconstructive skills were described as severely impaired.
Visual memory was also severely defective, especially when
learning material that lacked structure or associative quality.
Verbal memory was described as “impaired” when dealing
with material that was unstructured or unrelated. O’s chief
cognitive complaints concerning speech were not veriﬁed.
On the contrary, oral expression received the highest score
(94th percentile).
Inthisanalysisoftheclinicalneuropsychologicaldata,we
focuson testresultsthatarerelevantto memory function. Of
special interest are results from the Wechsler Memory Scale-
III (WMS-III) [47] and the California Verbal Learning Test-
II (CVLT-II) [48]. The WMS-III auditory immediate and
auditory delayed subtest scores were in the ∼1st percentile.
General memory was at the “borderline” level. Memory
deﬁcits were also revealed by the CVLT-II, where all but two
Z-scores ranged from ∼− 1t o∼− 4.
In our view, these substantial oﬀ-glycine deﬁcits are
highly unlikely to have been present in the on-glycine
periods when O obtained a verbal SAT score in the 90th
percentile and a 99th percentile score in the reading and
social studies subtests of the GED. Here we emphasize that
both the GED and the SAT scores were obtained in the
standard time periods. These test scores also seem to be
in marked contrast with the psychologist’s impression that
attention and executive deﬁcits at the time of testing (oﬀ-
glycine for 17 months) exerted considerable impact on tasks
requiring complex mental manipulation, self-monitoring,
multitasking, and working memory.
Further support for a cognitive improvement from
glycine treatment can be found in evidence that the oﬀ-
glycine deﬁcits seen in OP10 represent a decline from a
prior time. Such evidence derives from the Wechsler Test of
Adult Reading (WTAR) [49] in which word reading scores
(thought to be resistant to brain injury or other causes of
cognitive decline) are used to predict premorbid IQ scores.
The WTAR presumes that adult reading levels were achieved
before cognitive decline. Clear evidence for achievement of
adult reading levels can be seen in O’s 99th percentile score
on the reading and social studies subtests of the GED (age
26) and his 90th percentile score on the verbal part of the
SAT (age 27).
WTAR results (at age 30) obtained 17 months after
glycine cessation indicate that O’s actual Verbal standard
score, Full-Scale standard score, Perceptual Organization
Index score for the Wechsler Adult Intelligence Scale-III [50]
were14–17pointsbelowWTARpredictions(cumulativeper-
centage = 5–9%). A more dramatic diﬀerence of ∼30 points
between predicted and actual was seen for the Working
Memory Index scores (cumulative percentage = 1%). Here it
should be noted that working memory is central to cognitive
functioning and is strongly correlated with reasoning ability
[51]. Moreover, working memory is currently considered to
be a key determiner of ﬂuid intelligence [51, 52]. Given the
central importance of working memory and O’s high verbal
score on the SAT (reasoning test of the College Board) at
age 27 in OP5 (137-days on glycine) and the absence of any
infection-triggered or other obvious exacerbations since that
time, we suggest that the WTAR data are most consistent
with a cognitive decline as a result of glycine cessation in the
17-month period that preceded the test. Table 3 summarizes
educational and other cognitive data.
Another issue is the possible interference of obsessive
mentation with test performance. O’s father attended both
testing sessions to address this issue. His recorded notes
indicate that O reported no obsessions or mental rituals or
anyotherdiscomfortsordistractionsineithertestingsession.
O reported: “I gave it my all.” The clinical psychologist’s
report noted that O was euthymic and appeared to make
af u l le ﬀort and that test results for depression, anxiety,
and ADHD indicated that these factors did not impact test
results. Results were therefore judged to represent a valid
picture of cognitive status.
3.5.12. Adverse Eﬀects of High-Dose Glycine? Ingested glycine
appears to enter circulation rapidly, generating a sharp
rise in plasma glycine concentration. In O’s case, multiple
measurements at approximately two hours after completion
of consumption have yielded values ranging from ∼2600 to
∼3300μM, with an average of ∼2800. The time at which
peak concentration is reached is unknown, but may be
less than 2 hours after ingestion and may depend on the
rate at which glycine is consumed and on the presence
of other food in the stomach. On one occasion, a plasma
value obtained at 3 hours after glycine ingestion (∼1350μM)
was substantially less than values obtained at 2 hours (∼
2000–3000μM)(normalreference151–490μM).Onanother
occasion, 24 hours after terminating an extended period
of glycine consumption, plasma glycine was ∼280μM, a
base-line value in the reference range (151–490μM). This
observation is consistent with studies of healthy volunteers
by Hahn and Sandfeldt, who found the half-life of excess
plasma glycine to range from 40 to 100 minutes in many
individuals to 6 hours in one individual [53].
Hahn and Sandfeldt also found that glycine infusion in
amountscomparabletothoseusedinthisstudyinducedlittle
or no increase of plasma ammonia in most individuals [54].
However, about 10–15% of healthy volunteers developed
plasma ammonia levels in the 100μM range after i.v.
infusion of 20g of glycine [54]. O appears to be in this
category. For example, in a typical measurement, plasma
ammonia about 2 hours after glycine ingestion was ∼120μM
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was ∼15mmol/mol/creatinine (reference: 0.4–1.2). Several
physicians, including specialists on hepatic encephalopathy
and urea cycle disorders, have suggested that the mild
hyperammonemia seen in O is unlikely to cause harm.
Nonetheless, hyperammonemia represents an issue that, to
our knowledge, has not been studied in prior trials.
As noted previously, OP1 was terminated because of
a fever of 104.2◦F during an upper respiratory infection.
At that time, O and his parents could not recall a fever
this high in previous infections and worried that glycine
might cause elevated temperatures. However, no high fevers
have been experienced in the subsequent four years, during
which glycine was taken for 850 days. In this period, the
only precaution has been to terminate glycine at the ﬁrst
sign of an infection. Although there is no clear evidence
for glycine inducing higher-than-normal fevers, we include
these ﬁndings for future reference, since there is literature
suggesting a role of NMDAR-ST in the fever response to
bacterial toxins [55].
Mild weight loss with no obvious cause led to the
termination of OP9. On the basis of sporadic measurements,
weight declined from 184 pounds to 165 pounds over a
period of 22 weeks. Glycine consumption was completely
stopped and weight remained at this level for 17 weeks.
Weight then increased to 172 pounds over a period of 8
weeks. Over the next 6 months, weight gradually returned
to prior levels with no deliberate eﬀort to increase weight. As
notedinthesectionforOP10,therewerenosignsofanorexia
nervosa or other eating disorders. At this point there is no
clear evidence for glycine as the cause of weight loss.
In summary, available evidence suggests that high-dose
glycine treatment used for a total of 947 days in a ﬁve-
year observation period has not produced any detectable,
serious adverse aﬀects in an individual closely monitored
by his physicians. This observation is in agreement with the
apparent absence of serious adverse eﬀects in the 20 years of
glycine trials with schizophrenia [56].
4. Discussion
4.1. The Results of This Case Study Are Consistent with
the Possible Eﬃcacy of High-Dose Glycine Therapy. There is
substantialthird-partyobjectiveevidencethatOexperienced
unrelenting illness that generally increased in the 10 years
that preceded glycine treatment and that O’s education and
social life were profoundly disrupted.
Evidencefordisruptionofeducationresidesinacompre-
hensive set of third-party records on school attendance and
nonattendance, academic performance during attendance,
results from standardized academic tests, ﬁnancial records
from academic institutions, and written correspondence
from academic administrators and city truancy oﬃcials. For
8 years before glycine treatment, there was no attendance
of school or commercial tutoring. Resumption of education
following the initiation of glycine treatment is likewise
supported by comprehensive third-party objective evidence.
Over a period of approximately 2 years, evidence for
sustainedandincreasingimprovementresidesinthefactthat
O passed the high school equivalency exam, prepared for
the SAT test in a commercial course, preformed well on SAT
test and began college. Academic records indicate excellent
attendance and performance.
Disruption of education was accompanied by disruption
of social life and a housebound state. Evidence for a resump-
tion of social life following glycine treatment is likewise
supported by substantial third-party objective evidence. For
example, evidence for a resumption of social life resides in
email correspondence with classmates that relates to social
activities at speciﬁc events and locations in his city and
another city. Credit card records indicate the purchase of
clothes, attendance at restaurants and concerts in his city
and another city. Thus, there is clear, third-party objective
evidence for resumption of an active social life and normal
mobility in his city that is not subject to concerns about
subject, parental, or researcher bias relating to outcome
assessment.Thisevidenceforamajorreductioninpreglycine
life disruptions suggests a major improvement in the OCD
and BDD dimensions of O’s illness. However, before this
major improvement can be considered a genuine eﬀect of
glycine, it is necessary to rule out placebo eﬀects and a
spontaneous remission.
Given that placebo eﬀects derive from patient anticipa-
tions for treatment, there is the a priori expectation that
placebo eﬀects will not be durable in individuals expe-
riencing powerful, life-disruptive psychiatric illness. This
expectation has been conﬁrmed by Quitkin and coworkers
insystematicstudiesofplaceboeﬀectsindepression[57–61].
Speciﬁcally,thereisa marked tendency forplacebo responses
to occur abruptly within the ﬁrst two weeks and to disappear
within the ﬁrst 12 weeks of treatment. This placebo response
pattern is in contrast to what the authors regard as the
response pattern for a true pharmacologic response, where
the initial eﬀects appear after a period of two weeks and
tend to last 12 weeks or longer. The placebo response pattern
can, of course, be seen either with a true placebo or with
an active drug. These authors “conclude that a signiﬁcant
portion of relapses within the ﬁrst 6 weeks of treatment with
an active drug are not related to loss of a true drug eﬀect.
Rather some are related to loss of nonspeciﬁc placebo eﬀects,
and abrupt nonpersistent responses during drug treatment
are most likely the result of placebo eﬀects” [60]. They note
that the early occurrence of placebo eﬀects is consistent with
the notion that they derive from patient expectations [61].
Others have made similar observations [62]. In relation to
studies of OCD patients, Ackerman and Greenland [63]h a v e
noted that the observation of less improvement in longer
trials of active drugs may be due to placebo eﬀects from
expectations generated by side eﬀects: “It is possible that
in the early 10-week clomipramine and 8-week ﬂuvoxamine
trials, some of the subjects in the active treatment arms
responded to nonspeciﬁc study eﬀe c t s( s u c ha ss i d ee ﬀects).
In longer studies, that improvement was not maintained.”
Here it can be noted that Quitkin et al. [59] suggest that
“precise assessment of drug eﬀects probably requires several
months of observation.”
In view of the above considerations, we suggest that it
is highly unlikely that the objective, major, and long-lasting12 Neural Plasticity
Table 2: Summary of Changes in OCD and BDD in the ten observation periods.
OP1 On-glycine
203 days
Partial reduction of OCD and BDD. Partial elimination of housebound state. Increased mirror
tolerance. Barbershop haircuts. Partial resumption of social life. Attendance at social gatherings at
homes of family friends. Increased volition and study eﬀort. Obtained GED diploma. Improved
hygiene and attention to clothes. Sleep cycle spontaneously normalized.
OP2 Oﬀ-glycine
41 days
Partial loss of OP1 gains following infection with high fever. New hand washing ritual based on
fear of harm with mild impairment.
OP3 On-glycine
127 days
Rapid recovery from relapse in OP2 and further improvements in OCD and BDD beyond those
of OP1. Attended preparatory course for SAT.
OP4 Oﬀ-glycine
40 days No signiﬁcant change in OCD or BDD.
OP5 On-glycine
137 days
Further reduction in both OCD and BDD. Resumption of normal family social life in home for
ﬁrst time in 8 years. Preparation for SAT by self-study. Excellent SAT scores greatly increased from
initial practice test scores (see section on cognition). Housebound state eliminated but
community movement remained partially restricted. Improvements resistant to stress and
disappointment. Hand washing ritual that started in OP2 disappeared by end of OP5.
OP6 Oﬀ-glycine
220 days
Entered college at beginning of this period. In-class socialization with peers. Good academic
performance except for apparent cognitive decline after 21-26 weeks (see section on cognition).
No signiﬁcant change in BDD. Increased somatic/cognitive preoccupations with mild
impairment. After 10 weeks, a mild increase in line-crossing obsession.
OP7 On-glycine
254 days
Transferred to more competitive college. Consistent academic eﬀort with respectable grades.
Major reduction in OCD/BDD. No sensitivity to crime reports in news and increased community
mobility. Resumed hair combing in front of mirrors with partially covered face. Father-related
BDD by proxy disappeared. Improved family socialization and more order at home.
Somatic/cognitive preoccupations remained mild. Gains resistant to stress.
OP8 Oﬀ-glycine
46 days No signiﬁcant change in OCD or BDD.
OP9 On-glycine
332 days
Very high grades. Developed career ambition. Largely complete remission of line-crossing
obsession. Full community mobility and socialization with peers. First date with a girlfriend in 13
years. Reduced self-related BDD and mother-related BDD by proxy. Reduction of
somatic/cognitive preoccupations towards end of this period. Improved orderliness at home.
OP10 Oﬀ-glycine
541 days
Increase in self-related BDD and in mother-related BDD by proxy caused diﬃculties in social
interactions with mother, relatives, and family friends. Reduction in community mobility due to
partial return of major line-crossing obsession. Return of diﬃculty in making eye contact during
greetings and conversations. Reduced volition and orderliness at home. Partial relapse of OCD
and BDD occurred very slowly. Major decline in selective aspects of cognition relative to OP5.
changes in life activities that followed glycine treatment
represent a placebo eﬀect. Unlike placebo eﬀects, the change
that followed initiation of glycine treatment was not abrupt.
The subject and his parents report that the ﬁrst sign of
improvement (leaving home without parental escort for
the ﬁrst time in 5 years) occurred 5 weeks after initiation
of glycine consumption. Further improvement was also
gradual, with third-party objective evidence documenting
a gradual resumption of education and social life over
treatment periods totaling 150 weeks (in an observation
period of 5.3 years). This is much longer than the “several
months” described by Quitkin et al. [59]a ss u ﬃcient to
detect true drug eﬀects.
Although the above studies clearly suggest that eﬀects
generated by patient expectations tend to be transient, it
is nonetheless possible to observe some cases in which
improvement from a known placebo appears to be enduring.
For example, Quitkin observed sustained improvement in
placebo-treated individuals with depression [57]. In these
cases, the authors make the reasonable suggestion that the
improvement was more likely to have been a spontaneous
remission than a placebo eﬀect. Therefore, it is necessary
to consider the possibility that O’s enduring improvement
following initiation of glycine treatment was due to sponta-
neous evolution of illness.
We ﬁrst note that a spontaneous remission appears
unlikely on the basis of prior longitudinal studies, which
suggestthatbothOCDandBDDgenerallyhaveacontinuous
course, with spontaneous remissions being rare, especially
in SSRI-refractory cases [64–69]. Moreover, the occurrence
of both disorders together tends to be associated with a
worse prognosis. Although suggestive, these considerations
do not constitute deﬁnitive evidence against a spontaneous
remission in a speciﬁc case.
One approach to distinguish true eﬃcacy from spon-
taneous remission in a speciﬁc case is to determine if
deteriorations occur during periods of nontreatment. To
pursue this approach, this study was continued until we
obtained objective, third-party evidence for an unequivocal
deterioration during nontreatment that avoided concernsNeural Plasticity 13
Table 3: Summary of cognitive and educational data.
Age 7
Formal cognitive testing suggests mild deﬁcits,
including signs of deﬁcits in attention and working
memory.
Age 14
Poor retention of algebra topics during intensive
paternal tutoring. Same types of math errors seen in
Age-7 cognitive testing.
Age 17–25 No regular school or formal tutoring in the eight
years preceding glycine treatment.
Age 25
GED test taken in standard time period 145 days
after initiation of glycine treatment. Five GED
s u b t e s ts c o r e sr a n g e df r o mt h e6 7 t ht ot h e9 9 t h
percentile.
Age 27
SAT taken in standard time period 68 days after
resuming glycine in OP5. Verbal score = 90th
percentile. Math score = 50th percentile. Oﬃcial
scores were each 120–130 points higher than the
lowest practice tests.
Age 27
Paternal impression of rapid absorption of new
math topics is supported by college placement exam
taken just after end of glycine consumption for 138
days. College education initiated. Generally good
academic performance in English and Algebra
courses. The same types of math errors seen at ages 7
and 14 returned 21–26 weeks after glycine cessation.
Age 30
Formal cognitive testing 17 months after glycine
cessation revealed substantial deﬁcits in tasks
requiring manipulation of nonsequential items,
self-monitoring, response inhibition, and set
shifting. Visual-perceptual and visuoconstructive
skills were found to be severely impaired. Auditory
immediate and delayed scores on subtests of the
Wechsler Memory Scale III were in ∼1st percentile.
Memory deﬁcits were also revealed by the California
Verbal Learning Test-II. A diﬀerence of 30 points
between predicted and actual results was found for
the Working Memory Index of the Wechsler Test of
Adult Reading (cumulative percentage = 1%),
suggesting a cognitive decline from OP5 where high
verbal SAT performance was seen.
about subject expectations and outcome assessment bias
in the observations made by the subject, his parents and
researchers.
As noted for the long oﬀ-glycine periods, OP6 and
OP10, modest relapses were seen for OCD and BDD.
However, the clearest evidence of deterioration was for the
cognitive dimension of O’s illness. Most notably, third-party
objective evidence derived from clinical neuropsychological
testing in OP10 suggests substantial deﬁcits in selective
aspects of cognition by the end of this period. This testing
with formal methods was done by a neuropsychologist
who was blinded to psychiatric and treatment histories. A
comparison of this oﬀ-glycine data with the excellent SAT
scores obtained in the on-glycine period, OP5, suggests a
substantial decline in selective aspects of cognition in OP10
relative to OP5 levels, as discussed in Section 3.5.11.A l lo f
this evidence is objective except for some neuropsychological
tests that required subjective evaluation by the clinical
neuropsychologist, such as the Rey-Osterrieth test. In these
cases, any subjective judgments were made under blinded
conditions that precluded expectations of the neuropsychol-
ogist that were based on treatment history or psychiatric
diagnoses.
The possibility that treatment cessation could have
generated expectations in our subject that somehow aﬀected
his performance on the neuropsychological testing can
also be considered. We ﬁrst note that the subject reports
that he initiated testing because of speech diﬃculties. The
evaluation revealed normal verbal ﬂuency but did reveal
multiple other deﬁcits. The point here is that the deﬁcits
found were diﬀerent from the subject’s initially expressed
complaints. Further evidence against expectations for a
decline in memory after glycine cessation reside in the fact
that in serial interviews, the subject has expressed doubts
about the validity of the tests for memory deﬁcits and has
noted that friends have commented on his excellent memory
of the distant past. Moreover, he has not resumed high-
dose glycine consumption in response to the test results.
It can also be noted that the neuropsychologist reported
that the subject was euthymic and appeared to make a full
eﬀort.
On the basis of the above considerations, we suggest
that the third-party evidence that we present for a cognitive
deterioration is either fully objective evidence or is evidence
that is not compromised by an absence of blinds or by
subject expectations. An important point is that the selective
cognitive deterioration was substantial, since some WMS-
III scores were in the ﬁrst percentile and since the Rey-
Osterrieth copy score was more than 8 standard deviations
below the mean. We suggest that it is unlikely that scores
on these tests would have been much lower had they been
measured before the initiation of glycine treatment.
In summary, we suggest that the bias-free evidence that
we present for a major improvement of OCD and BDD
during treatment and for a major deterioration of selective
aspects of cognition during nontreatment is consistent with
the possible eﬃcacy of glycine.
4 . 2 .T h eF i n d i n g so fT h i sC a s eS t u d yM a yH a v eG e n e r a l i t y .
In response to the success achieved in the ﬁrst year of this
study, a collaborative initiative was begun to test glycine with
otherOCDpatients.Theﬁrstaspectofthisinitiativehasbeen
a placebo-controlled study in which glycine was used as an
adjunct to pre-existing pharmacotherapy. The 5 individuals
who were treated with glycine had a mean decrease in Y-
BOCS[70]scoreof6.04pointswhereasthe9subjectstreated
with placebo experienced a 1.00 point decrease (P = .053)
(Greenberg, Benedict, Doerfer, Perrin, Panek, Cleveland,
and Javitt, Adjunctive glycine in the treatment of obsessive-
compulsive disorder in adults [71, 72]). Although much
larger studies are needed to determine the frequency of
responders, the results of Greenberg et al. are in agreement
with this case study and raise the expectation that additional
OCD patients will be glycine responders. To facilitate large
trials, it would be desirable to identify glycine-responsive
subtypes. The comprehensive case description in this paper
has been motivated, in part, by this goal.14 Neural Plasticity
4.3. The Results of This Case Study Have Been Achieved with
a Single Psychotropic Reagent. To our knowledge, this case
study represents the ﬁrst use of high-dose glycine with OCD
orBDD and the ﬁrst use of glycine alone with any psychiatric
disorder. In addition, there was no psychotherapy or behav-
ior therapy during the 5-year period of monitoring. Thus,
this study is free of factors that confound the interpretations
of many studies. Given the magnitude of the improvement
seen in this study, we suggest that trials of glycine alone be
considered for future studies.
4.4. The Results of This Case Study Motivate Long Trials of
Glycine. In agreement with prior studies of glycine as an
adjunct to conventional medication in schizophrenia [73],
an initial response to glycine treatment was detected in this
study only 23 days after reaching the target dose. However,
the improvement reported for the ﬁrst 12 weeks of treatment
wasonlyasmallfractionoftheimprovementreportedforthe
ﬁveon-glycinetreatmentperiodsthatextendedoveraperiod
of almost four years. This suggests that the short clinical
trials used in the past, for example, 12 weeks, may have failed
to reveal the full therapeutic potential of high-dose glycine
treatment in the disorders studied.
4.5. Do the Results of This Case Study Support the Hypo-
NMDAR-ST Hypothesis? The results of this high-dose
glycine trial with refractory OCD, BDD, and cognition
deﬁcits are in unequivocal agreement with the main predic-
tion of the Hypo-NMDAR-ST hypothesis that inspired its
initiation.However,itisalsonecessarythatthishypothesisbe
compatible with prior, well-established ﬁndings for NMDAR
neurotransmission.
Since our hypothesis was constructed to explain the
apparent behavioral eﬀects of clarithromycin, which has
been reported to inhibit NMDAR-ST at a downstream
point, it is reasonable to consider if other downstream
NMDAR-ST inhibitors have similar eﬀects. There are many
studies of NMDAR inhibition on human behavior, but,
to our knowledge, all employ global inhibitors, such as
phencyclidine and ketamine, that act on the NMDAR itself.
Thus, a direct comparison is not possible. With this caveat in
mind, it is nonetheless of interest to consider known eﬀects
of ketamine and phencyclidine in relation to this study.
To our knowledge, controlled studies with phencyclidine
and ketamine have considered either healthy subjects or
subjects with schizophrenia [38, 74]. In healthy subjects, the
basic ﬁndings are deﬁcits of cognition and other signs and
symptoms that are schizophrenia-like [38, 74]. In subjects
with schizophrenia, a worsening of existing or reactivation
of previously controlled symptoms is the main presentation
[38, 74]. In these very short-term experiments, signs and
symptoms of OCD, to our knowledge, have not been
reported. Although visual distortions of body parts are a
prominent consequence of ketamine and phencyclidine [38,
74] and somatosensory abnormalities have been suggested
to be an aspect of BDD deriving from parietal-occipital
abnormalities[75,76],full-ﬂedgedDSM-IVBDDhasnot,to
our knowledge, been reported in these experiments. At ﬁrst
sight, these ﬁndings might be considered incompatible with
our hypothesis. However, general considerations suggest that
local defects in NMDAR-ST could be speciﬁc for OCD/BDD.
The absence of such defects in normal individuals and in
individuals with schizophrenia would explain the absence
of OCD/BDD in the reported ketamine and phencyclidine
experiments. Here it can be noted that disorder-speciﬁc
defects appear to have inﬂuenced the exacerbations induced
by clarithromycin in other cases. For example, in one
case, previously controlled bipolar disorder was reactivated
[77]. In another, previously controlled posttraumatic stress
disorder was reactivated [78].
It can also be noted that disorder-speciﬁc defects for
OCD and BDD are plausible in relation to known neuro-
biology. Given that SSRIs are the ﬁrst line drugs for both
OCD and BDD, it is possible that abnormal serotonin neu-
rotransmission plays a causal role in these disorders in some
individuals. This raises the possibility of a local, OCD/BDD-
speciﬁc defect that is restricted to serotonergic neurons of
the raphe nuclei. Recent evidence indicates that NMDAR-
ST regulates the ﬁring rate of these neurons [79], suggesting
that deﬁcient NMDAR-ST could lead to an abnormal ﬁring
rate. The more downstream the defect the more likely it
will involve the molecular systems that produce, release,
andtransportserotonin.Recentclariﬁcationsofmechanisms
regulating serotonergic neurotransmission [80–84]r e v e a la
complexpictureinwhichmultipleprocessescoupleNMDAR
input with serotonin release/reuptake. Defects occurring in
these processes could represent OCD/BDD-speciﬁc defects
in NMDAR-ST.
Another possibility is a deﬁciency of NMDAR-ST in
GABA-ergic inhibitory interneurons (abundant in both
the dorsal and median raphe nuclei [85]) that regulate
serotonergic neurons. This scenario can be seen as a variant
of the elegant and inﬂuential theory of Olney et al. in which
deﬁcient NMDAR-ST leads to loss of feedback inhibition
[37]. The core principle of this theory, which goes beyond
“hyperglutamatergic” or “hypoglutamatergic” models [14],
is that glutamate “functions not only as a straightforward
excitatory agent in the brain, but as a major regulator of
inhibitory tone” [37]. Local NMDAR-ST deﬁcits restricted
to interneurons that regulate serotonergic neurons could
reasonablybeexpectedtoleadtoabnormalserotonergictone
and the emergence of OCD/BDD.
In both of the above scenarios, there is an absence
of the more widespread perturbations expected for global
NMDAR-ST inhibition by ketamine and phencyclidine. The
absence of these perturbations would be compatible with
the emergence of OCD/BDD without the schizophrenia-
like symptoms seen with ketamine and phencyclidine.
Also, in both scenarios, it would be reasonable to expect
worsening of signs and symptoms by an inhibitor and
improvement from an enhancer of NMDAR-ST. However,
it should be emphasized that the above analysis is intended
only to suggest plausibility of disorder-speciﬁc defects,
not to propose a speciﬁc mechanism for the case under
study.
AlthoughOCDandBDDhavenotbeenseeninketamine
experimentswithhumans,someofthecognitivedeﬁcitsseenNeural Plasticity 15
in O show substantial overlap with the cognitive eﬀects of
ketamine. A consistent ﬁnding in multiple ketamine studies
is a robust, dose-dependent decrease in verbal declarative
memory that occurs at doses below those that induce
schizophrenia-like symptoms [38, 86]. Deﬁcits in verbal
memory and learning in ketamine experiments have been
assessed with story recall and list learning tests. For example,
Newcomer et al. [86] found a dose-dependent decrease in
verbal memory under ketamine using a paragraph recall test
from the Wechsler Memory Scale-Revised [87]. Immediate
and delayed recall scores from this study can be compared
with O’s corresponding scores on a revised version of this
test, the WMS-III. O’s Auditory Immediate and Auditory
Delayed scores were in the ∼1st percentile. In other ketamine
studies [88–90], a robust decline in verbal memory has been
found with list learning tests such as the Hopkins Verbal
Learning Test (HVLT) [91]. These results can be compared
with the signiﬁcant deﬁcits seen in O’s scores on the CVLT-
II [48], where the T score for Trials 1–5 was ∼36 (Z =
−1.4) and Z-scores for delayed recalls (free and cued) ranged
from ∼−2t o∼−2.5, except for the short delay free recall,
which was ∼− 1. The Z-score for total hits was ∼− 4.
Thus, O’s oﬀ-glycine deﬁcits in verbal memory are strongly
reminiscent of those induced by ketamine. This similarity
is clearly supportive of our hypothesis. Also supportive are
O’s very high on-glycine scores on the GED and verbal SAT
tests (99th and 90th percentiles, resp.), which suggest much
improvedverballearningandmemoryinanon-glycinestate,
as discussed above.
The ﬁnding that ketamine-induced cognition deﬁcits
appear at doses lower than those needed for other types
of symptoms [38, 86, 92–94] is also of relevance to our
hypothesis. Assuming that an endogenous NMDAR-ST
defect would mimic ketamine, this ﬁnding leads us to expect
thatthereturntoadeﬁcientNMDAR-STstateaftercessation
of glycine would manifest itself with a cognitive relapse
whose emergence is earlier and more pronounced than
the relapses for other categories of signs and symptoms.
Our data from OPs 6 and 10 appear to be consistent with
this prediction. Also of relevance is the fact that in the
initial emergence of illness in early childhood, diﬃculties
incognitionappearedbeforeobsessive-compulsivebehaviors
and BDD-related signs and symptoms.
Finally, we note that additional support for our Hypo-
NMDAR-ST hypothesis can be found in the course of O’s
illness. Speciﬁcally, it is known that NMDAR inhibition
has mild behavioral eﬀects in childhood and much larger
eﬀectsafterpuberty[95–100].Assumingthatanendogenous
NMDAR-ST defect would imitate an inhibitor, it follows that
O’sverymildillnessinchildhoodandtheemergenceofmuch
more incapacitating illness after age 15 are consistent with an
NMDAR-ST deﬁcit.
4.6. Do the Results of This Case Study Support Alternative
Hypotheses? Although the ﬁndings of this study support the
Hypo-NMDAR-ST hypothesis on which it is based, it is
appropriatetoconsiderourﬁndingsinthelightofalternative
hypotheses proposed by others.
4.6.1. Is O’s Case an Example of PANDAS? One of the
deﬁning features of the PANDAS subtype is the occurrence
of exacerbations with sudden, abrupt onset [25]. The
exacerbations are described as “typically quite dramatic,
with patients reporting that their symptoms “...came on
overnight” or “...appeared all of a sudden a few days after
I had a sore throat.”” The ﬁne details of O’s exacerbations are
not congruent with this picture. For O’s age-19 exacerbation
that followed a positive throat culture, detailed notes of
O’s father indicate an improved relationship with his son
during the acute phase of the infection. The behavioral
deterioration is described as beginning “as soon as the
infection cleared.” Worsening of existing symptoms (e.g.,
line-crossing obsession) occurred 24 days after the positive
throat culture. Episodes of violent imagery appeared for the
ﬁrst time approximately 40 days after the positive throat
culture. In addition to the slower kinetics, O’s nonre-
sponse to IVIG therapy is unlike some PANDAS patients
[26].
4.6.2. Are the Findings for O’s Case Compatible with an
Autoimmune Etiology? Although, O’s case cannot be classi-
ﬁed as a clear case of PANDAS, it is still possible that it
involves an antigen-speciﬁc autoimmune response induced
by GABHS. There are, of course, multiple precedents, both
experimental and theoretical, for the induction of antigen-
speciﬁc anti-self-immune responses by foreign antigens that
cross-react with self-epitopes or interact with self-receptors
[101–103]. Thus, the occurrence in O of two exacerbations
following probable GABHS infections is immediately sug-
gestive of an antigen-speciﬁc autoimmune mechanism. This
follows from the major precedent residing in rheumatic fever
(RF) as an antigen-speciﬁc autoimmune disease primed by
G A B H S .Ac o m p a r i s o no fO ’ si l l n e s sw i t hR Fi st h e r e f o r e
warranted.
As expected for a pathogen-induced, antigen-speciﬁc
autoimmune disease, recurrences of RF in adulthood are
associated with probable reinfection with GABHS, often
as a result of known, close contact with children having
GABHS infections [104]. The time interval between an
initial occurrence of acute RF in childhood and a subse-
quent occurrence in adulthood can be multiple decades.
During these long periods, there is an annual occurrence of
upper respiratory viral infections, some of which are “ﬂu-
like.” As expected for infections which are unlikely to be
antigenically related to GABHS, there is no retriggering of
RF. Another point is that penicillin prophylaxis is eﬀective
in preventing a return of RF [105]. This would not be
expected if viral infections signiﬁcantly trigger recurrence of
RF.
In contrast to RF, exacerbations in O’s case and in some
PANDAS cases [25] appear to follow both GABHS and non-
GABHS infections. It appears that Sydenham’s chorea, a
sequela of RF, can reoccur without GABH infection [106].
One might propose that, in these cases, antigen-speciﬁc
clones primed by an initial GABHS infection are somehow
retriggered by other pathogens, such as viruses. However,
the failure to see this phenomenon in RF represents a major
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One possibility is that the putative brain injury responsi-
bleforO’scasearisesfromnonantigen-speciﬁcconsequences
of GABHS and other infections. Such a mechanism would
be compatible with recurrence from both GABHS and non-
GABHS infections and would not be incompatible with
the peripheral antibrain antibodies reported in the recent
literature [107–111], since the latter could be a result (rather
than a primary cause) of brain injury due to the release of
antigens from an immunologically protected site. Here it is
of interest that Husby et al. who in 1976 found antistriatal
antibodies in patients with Sydenham’s chorea [112], also
found similar titers of antistriatal antibodies (using identical
techniques) in patients with Huntington’s chorea [113]. This
led in 1977 to the suggestion that Huntington’s chorea
could be an infection-triggered autoimmune disease. The
latter is now known to be a polyglutamine disease [114]
that involves preferential death of striatal neurons [115]. In
brain-injury models of this type, it is formally possible that
antibrain antibodies arising from brain injury could play a
secondary role in pathogenesis. However, the demonstration
that such antibodies play a causal role is a diﬃcult task that
is technically inaccessible in the absence of validated animal
models [116, 117], which are unavailable for psychiatric
disorders that involve high-level human thinking.
4.6.3. Is O’s Illness due to a Primary Vascular Defect? The four
SPECT scans done over ﬁve years provide evidence for stable
and sustained hypoperfusion (Figure 1, Appendix A.3). The
cause of this hypoperfusion is unknown. One possibility is
that it reﬂects a primary vascular defect of long standing that
creates a susceptibility to psychiatric illness. In this context,
one is reminded of the interesting proposal by Hanson
and Gottesman that vasculature-inﬂammatory defects are a
root cause of psychiatric illness in subsets of patients with
schizophreniaandotherpsychiatricillnesses,includingthose
associated with GABHS infections [118]. They postulate “a
chronic smoldering inﬂammation of the vasculature” that
is episodically triggered to cause brain injuries leading to
psychiatric illness [118] .O ’ sa b n o r m a lS P E C Ts c a n s( w i t h
ad i ﬀerential diagnosis that includes “vasculitis”) and his
exacerbations following infections suggest consideration of
the theory of Hanson and Gottesman in future studies.
4.7. Are O’s SPECT Scans Typical of Other Patients with
Similar Diagnoses? In the literature on OCD, SPECT scans
most commonly show hyperperfusion in frontostriatal areas,
but hypoperfusion is prominent in a signiﬁcant fraction
of patients [119, 120]. To our knowledge, in cases where
hypoperfusion was seen, heterogeneity was not noted. In a
rare SPECT study of BDD, Carey et al. reported that both
regional hypoperfusion and hyperperfusion could be seen
in six subjects with BDD [75]. All showed hypoperfusion
in the temporal region. Of special interest are 2 young
adult male BDD patients with no other current comorbidity
who showed heterogeneous hypoperfusion in the occipital
and parietal lobes. As seen in Figure 1 (Appendix A.3),
heterogeneous hypoperfusion is a distinctive feature of O’s
SPECT scans, suggesting that his scans most closely resemble
the BDD scans.
4.8. Possibilities for Improved Monitoring and Treatment. The
detection of brain glycine by single voxel MRS was initially
accomplished only in individuals with genetic or other
defectsthatleadtounusuallyhighlevelsofglycine[121,122].
Our preliminary results in 2004 with a 3Tesla machine
(Figure 2, Appendix A.4) raise the possibility that high-dose
glycine treatment causes suﬃcient elevation of forebrain
glycine to permit detection using standard procedures with
optimal echo times. Future attempts to conﬁrm this ﬁnding
will beneﬁt from recent improvements in techniques and the
emergence of 7Tesla scanners [123–125].
The opportunity to monitor glycine concentrations in
speciﬁc brain regions will permit the exploratory studies
needed to identify the oral dose required to get the
desired concentrations in relevant brain regions. Studies in
rodents suggest that in much of the forebrain, endogenous
glycine concentration is substantially lower than that in
the hindbrain and spinal cord [126], making the ability
of MRS to measure glycine concentrations in small voxels
an important advantage. As noted previously, high-dose
glycine treatment may lead in some individuals to mildly
elevated plasma ammonia. This could lead to elevated levels
of ammonia in the brain. Studies in rats have indicated
that moderate levels of chronic hyperammonemia inhibit
NMDAR neurotransmission [127]. This raises the possibility
that optimal glycine therapy in individuals with elevated
ammonia would require a coadministered agent to control
ammonia. There is also the possibility that excess levels of
glycine in the brain may lead to increased in situ production
of ammonia. These issues can likely be addressed with the
new high-ﬁeld scanners [128–130].
5. Conclusion
Trials of glycine with schizophrenia have prompted a
search by pharmaceutical companies for drugs that enhance
NMDAR neurotransmission. While this study suggests that
these drugs may also be useful with OCD and BDD, it is
likely that a signiﬁcant period of time may elapse before
they become available. We therefore emphasize that glycine
is available here and now and at very low cost. This point is
of great signiﬁcance to patients, who need immediate relief
from what is often severe and unrelenting illness. With these
considerations in mind, we suggest that the ﬁndings of this
study motivate further exploration of the eﬃcacy and safety
of glycine as a treatment of OCD and BDD as well as further
study of the Hypo-NMDAR-ST hypothesis that motivated
this treatment.
Appendix
A.Detailsof PreglycineIllnessand
Medical/Radiologic History
A.1. Signs and Symptoms of Illness in the Preglycine Period
A.1.1. OCD Signs and Symptoms
Obsessions. In the preglycine period, O and his parents
report that obsessive mentation was continuously presentNeural Plasticity 17
from the time of eruption of frank illness at age 15. The
most impairing obsession was a line-crossing obsession,
which would be triggered (or intensiﬁed) when O would
see a person in his neighborhood whom he considered
to be likely to commit a violent, personal crime. Reports
of crime in the news media also activate the obsession,
provided that they occur in a “good” neighborhood. Crime
events in a “bad” neighborhood are of no concern, since,
in the latter case, there is evidently no line-crossing. The
line-crossing obsession is highly ego-dystonic. It is also
a “reactive obsession” in the classiﬁcation framework of
Lee and Kwon [131], in which obsessions responsive to
perceived environmental stimuli are called “reactive.” By not
leaving his home O was able to reduce distress by avoiding
exposure to environmental intensiﬁers, but this generated
major impairment by disrupting education and social life.
Obsessions involving violent imagery are also an impor-
tant feature of O’s illness. The ﬁrst occurred during the
age-19 exacerbation that followed bilateral ear infections.
Violent imagery involved images of a knife cutting his father
causing extreme fear and distress. As O’s father noted in
a letter to a psychiatrist: “The terrifying thoughts are truly
agonizing and he begs for relief while holding my hand and
literally trembling.” It should be noted that two psychiatrists,
who were consulted at this time, concluded that the violent
imagery did not involve hallucinations. Violent imagery with
intense distress has occurred only during the three major
exacerbations and thus represents a distinctive “signature”
of such exacerbations. Since these episodes are not triggered
by perceived environmental stimuli. O’s episodes of violent
imagery can be classiﬁed as “autogenous obsessions” in the
classiﬁcation framework of Lee and Kwon [131]. It is of
interest that O reports that episodes of violent imagery are
not associated with anger, which is in contrast to reactive
obsessions.
Ritualistic Behaviors. According to O’s father, activation
of the line-crossing obsession would invariably lead to a
stereotypic conversation that was highly repetitive due to
frequent but incomplete attempts to make a particular point.
O’s father would provide repeated reassurances that O’s
obsession-related fears were unfounded. O’s father refers to
this type of conversation as a “talk-through.” Talk-throughs
were not restricted to the line-crossing obsession, but could
concern any OCD-related obsession or the BDD-related
excessive preoccupations (see below). O’s father emphasizes
the distinct, “qualitative” diﬀerence between a talk-through
and a normal conversation that progresses in a linear fashion
from one point to another.
Although talk-throughs have features of reassurance
rituals, they are more complex as they frequently involved
an outburst of verbal anger. O’s father notes that when
talk-throughs were avoided for several days there would
be a stronger outburst of anger when they were resumed.
After about 1 hour of the repetitive conversation and after
an outburst of anger, the psychic distress, including anger,
would usually be dissipated until they returned the next
day. Talk-throughs were a daily feature in much of the six
year period that preceded high-dose glycine treatment. At
times of peak illness, they consumed multiple hours per
day.
Other ritualistic behaviors are reported to have included
prayer, wall-touching, jumping into bed, and turning lights
on and oﬀ a n dw e r ed o n ei nr e s p o n s et of e a ro fh a r m .
O indicates that fear of harm could either be for himself
or for his parents, especially his father. Most of the rituals
d o n et op r e v e n th a r mh a dt ob ed o n e“ j u s tr i g h t . ”I ns o m e
cases, rituals had to be done a large number of times or
according to a numerical pattern (in groups of 30 in one
case).
Prior to the age-22 exacerbation that followed antibiotic
treatment for H. pylori, there were a number of “just right”
rituals but they were minor in relation to the reassurance
rituals associated with the line-crossing obsession. Following
the antibiotic treatment for H. pylori, O’s father’s diary
indicates a very large increase, over a period of about two
months,inaprayerritualinwhichOwouldsuddenlydropto
his knees. Dropping to his knees had to be done “just right.”
This ritual was frequently performed throughout an entire
day, leading to knee calluses.
A.1.2. BDD Signs and Symptoms. In periods when O’s
BDD signs and symptoms were at their peak, O’s father
reports that O would spend most of a day “working on the
mirror,” an activity that would involve repeatedly checking
his appearance in a mirror in order to get a good impression
of his face. Rare good impressions were always followed by
numerous disturbing impressions that were often associated
with verbal anger. O’s parents report that this activity
clearly appeared to intensify distress and to increase O’s
preoccupation with his presumed facial defects.
In addition to the above self-related BDD, there was
a “BDD by proxy” for his mother’s and father’s faces.
Speciﬁcally, there was the fear/belief that they were ugly and
that he looked like them. “BDD by proxy” ﬁrst emerged
at age 19, several months after the ﬁrst infection-associated
exacerbation and led to a general avoidance of his mother
and restricted viewing of his father.
In periods when O was not spending multiple hours per
day “working on the mirror,” there was complete avoidance
of mirrors or other reﬂective surfaces or photographs of
himself. Activities were restricted by mirror avoidance and
inability to handle photo-identiﬁcation. Likewise there was
avoidance of social events as a result of a fear that someone
wouldsaythathewasuglyorlookedlikehismotherorfather.
All of this reinforced O’s tendency to be housebound, adding
to the similar eﬀects of the line-crossing obsession. Being
housebound reduced distress but led to major impairment
by disrupting education and social life.
A.1.3. Somatic Preoccupations. Somatic complaints associ-
ated with dysphagia, muscular discomforts and discomforts
at joints and the vasculature (cold hands, hot hands,
palpitations) are another distinctive aspect of O’s behavior.
The sites of discomfort are reported to have been stable over
time,althoughcomplaintsataparticulartimeusuallyinvolve
only a subset of sites.18 Neural Plasticity
Table 4: Count rates in counts per minute for Age-22 SPECT scan shown in Figure 1.
Slice location Region Left Right
Basal ganglia 1313 (+1.7%)∗ 1322 (+2.4%)
Thalamus 1205 (−6.6%) 1182 (+8.4%)
Cerebellum 1311 (+1.6%) 1270 (−1.6%)
2.5cm above
canthomeatal line
Medial frontal 970 (−24.8%)∗∗ 949 (−26.5%)
Lateral frontal 974 (−24.4%) 974 (−24.4%)
Anterior temporal 1243 (−3.7%) 1283 (−0.6%)
Posterior temporal 1189 (−7.9%) 1066 (−17.4%)
5.0cm above
canthomeatal line
Occipital 1027 (−20.4%) 1047 (−18.9%)
7.0cm above
canthomeatal line
Superior frontal∗∗∗ 1002 (−22.4%) 1059 (−17.9%)
1007 (−22.0%) 1029 (−20.2%)
Midparietal∗∗∗ 1059 (−17.9%) 1111 (−13.9%)
997 (−22.7%) 1102 (−14.6%)
∗Percent diﬀerences are relative to the average of the cerebellum count rates.
∗∗Ar e d u c t i o n>12% is considered clinically signiﬁcant.
∗∗∗For superior frontal and midparietal regions, duplicates were quantitated.
The possibility that O’s somatic complaints represent
hypochondriasis was reviewed by the OCD specialist con-
sulted at age 19. O’s father’s notes and the chart for these
consults indicate that hypochondriasis was not found. Thus,
O’s somatic concerns are not presented as improperly held
beliefs or fears about speciﬁc illnesses; rather, they are
presented as complaints about discomforts at body sites
with claims that they impede his functioning. Thus, O’s
somaticcomplaintsarediﬀerentfromthesomaticobsessions
often reported for OCD, which are typically concerned
with fears of illness rather than discomforts at body sites
[132].
In the recent interviews, O has reported that discomfort
in a particular joint increases gradually until it reaches the
pointwherehefeelsaneedto“pop”thejointtoeliminatethe
discomfort. The discomfort gradually returns and the cycle
repeats. It appears that the action of joint popping does not
initselfgenerateimpairment,sinceitisdoneonlyafewtimes
per day. Here we note that O never received a diagnosis of a
ticdisorder.Moreover,ithasnotbeenpossibletoidentifyany
tic-like behaviors for O’s other somatic preoccupations.
One possible explanation of O’s somatic preoccupations
is that they reﬂect, at least in part, an intrinsic hyper-
sensitivity to body sensations. This has been described for
individuals with Tourette syndrome, which, historically, has
been known to occur often with OCD [133] and which
may therefore share causal factors. The joint discomfort and
its relief by “popping” closely resemble the site sensitivity
and premonitory urges reported for individuals with TS
[134]. As Cohen and Leckman have noted [135]: “Patients
with TS are remarkably sensitive to and are easily captured
by changes in the sensory world...” Although, O has not
received a diagnosis of TS and does not appear to cross
the threshold for a tic disorder, it is possible that TS and
OCD as it occurs in O share causal factors, one or more of
which generate the sensory hypersensitivity. This possibility
is supported by a more recent characterization of sensory
phenomena in OCD, OCD+TS, and TS [136].
It should be emphasized that in the preglycine period,
somatic preoccupations were seen by O’s parents to be
“almost negligible” in relation to major OCD and BDD
presentations.ItwasduringOP6(theﬁrstlengthyoﬀ-glycine
period) that these preoccupations were ﬁrst seen to cause a
mild but clear impairment.
A.1.4. Cognitive Preoccupations. In addition to somatic com-
plaints, O has frequently complained since age 20 about
diﬃculties in speech production, speciﬁcally an inability to
ﬁ n dw o r d sa n dp h y s i c a ld i ﬃculties in speech production.
At the end of Observation Period 10 (see Section 3.5.11),
O initiated an examination by a speech pathologist, which
revealednospeechdeﬁcitsbutdidrevealamemorydeﬁcit.In
a subsequent neuropsychological evaluation, oral expression
was in the “superior” range and represented the highest of
all scores. On this basis, we tentatively refer to O’s speech
complaints as “cognitive preoccupations.” However, it is
possible that the speech-related complaints are an inaccurate
description of genuine cognitive deﬁcits that were revealed
in the neuropsychological evaluation (see Section 3.5.11). In
our view, available data do not allow a ﬁrm conclusion.
Additional documentary material on methods
and behavioral phenomena is at www.informat-
icpsychiatry.org/glycine.Neural Plasticity 19
21 20 19 18
17 16 15 14
13 12 11 10
9 8 76
Post
R
i
g
h
t
Transverse
Figure 1: Age-22 SPECT scan showing prominent and heterogeneous hypoperfusion. One color step equals a 10% change in perfusion. The
highest perfusion is indicated by white. See text for acquisition conditions and Table 4 for results of semiquantitative analysis.
A.2. General Medical History. Except for his psychiatric
disorder, O has been in good general health all of his
life. During pregnancy, ultrasound-guided amniocentesis
was done to rule out Down syndrome. No chromosomal
abnormalities were found. Records indicate that delivery was
by C-section because of placenta previa. Apgar scores were
9, 9, and 9 at 1, 5, and 10 minutes, respectively. Birth weight
was 7.75 pounds. Maternal and paternal ages at birth were 39
and 36, respectively. Developmental abnormalities were not
noted by parents or pediatrician. Infectious disease history
has been unremarkable except in relation to exacerbations of
psychiatric illness. Raynaud’s disease was ﬁrst noticed at age
21 just after the end of a taper of paroxetine from 70mg/day
to 0mg/day. It has been witnessed on several occasions in
clinical exams and continues to the present day. At age 26,
orthopedic and genetic consultations both revealed a mild
connectivetissuedisorder(megacephaly,archedpalate,striae
distensae, lax joints, and pectus excavatum) that could not
beidentiﬁedwithknowndisorders.Collagentestingrevealed
noabnormalities[137].Threeechocardiograms,doneatages
21, 25, and 29, were described as normal except for a “trivial
aortal insuﬃciency” that was noted for the ﬁrst two but
not the last, which was done four years after initiation of
glycine treatment. Mild, sporadic dysphagia was ﬁrst noted
at age 17. An upper endoscopy at age 29 revealed a Shatzky
ring and eosinophilic esophagitis. Other mild conditions are
recurrentotitisexternaandrecurrentoralstomatitisthatwas
noted as early as age 7, when parents recall a prescription for
lidocaine.
In general, neurological exams have been unremarkable
except for the conﬁrmation of psychiatric diagnoses. How-
ever, at age 15, an initial diagnosis of temporal lobe epilepsy
was discounted after discovering an electrode artifact in the
EEG. Trigeminal neuralgia, a diagnosis that was described
as unusual for a 15-year old, was suggested as a possible
alternative. The report emphasized that the symptoms could
notbegeneratedintheexamination.Subsequentrecurrences
of these symptoms, if any, appear to have been very
minimal. Also, at this time, a neuroopthalmologist found a
convergence insuﬃciency that gradually normalized without
treatment, as found in a later examination at age 18 by the
same neuroopthalmologist. An EEG at age 26 and after 191
days of glycine treatment was normal.
A.3. Brain SPECT Scans. Objective evidence for a CNS
abnormality resides in four SPECT Scans (technetium-99m-
hexamethyl propylamine oxime (Tc-99m-HMPAO))done at
ages 22, 23, 25, and 27. All scans were done under standard
clinical conditions for a resting scan. Approximately 20 mCi
of Tc-99m-HMPAO were injected into the patient while eyes
were open in a quiet, dimly lighted room. No caﬀeine or
medications were taken in the 3 days before the scan. O is
a nonsmoker and is right-handed. Approximately one hour
after tracer injection, scans were done with a three-headed20 Neural Plasticity
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Figure 2: Magnetic Resonance Spectrum from 2.5cm Voxel in
Right Medial Frontal Region 4.5 Hours after Consumption of
25Grams of Glycine + 3 Grams of Arginine. TE: echo time; TR:
repetition time; NEX: no. of excitations; MI: myo-inositol; Cho:
choline; Cr: creatine; NAA: N-acetylaspartic acid. See text for
additional details.
camera.Imageswerereconstructedinthetransaxial,coronal,
and sagital planes. According to the report for the age-
22 scan, marked heterogeneous and decreased cortical
uptake was noted throughout both cerebral hemispheres.
In addition, severe white matter hypoperfusion was also
noted. The report also indicates that the observed pattern
is often secondary to vasculitis or encephalopathy of an
infectious or toxic nature, for example, shearing injuries,
cocaine abuse or Lyme disease. O was tested three times
for Lyme disease with negative results and is reported to
have never experienced a shearing injury. Careful inquiry
suggests that he has never engaged in substance misuse.
Systemic lupus erythematosus (SLE) is another illness that
can be associated with heterogeneous brain SPECT scans. An
evaluation by a senior rheumatologist did not ﬁnd SLE. A
representative scan is shown in Figure 1.
A semiquantitative analysis of the age-22 SPECT scan
using the procedure of Mountz et al. [138] is shown in
Table 4. Values that are 12% or more below the cerebellum
average are considered pathological. The right medial frontal
regionshowedthelowestlevelofperfusion,whichwas26.5%
below the average of the cerebellar values. As indicated,
the frontal, parietal, right posterior temporal and occipital
areas are down more than 12%, whereas the basal ganglia,
thalamus, anterior temporal, and left posterior temporal are
not.
A second scan was done at age 23 and a third at age 25
just before the initiation of high-dose glycine treatment. The
fourth scan was done three days after stopping a 138-day
glycine treatment period. At the level of clinical evaluation,
these three scans are equivalent to each other and to the
prior scan. In summary, the SPECT scans show substantial
abnormality of unknown cause that is stable over a ﬁve
year period. No eﬀect from glycine treatment is detectable.
However, it should be noted that 3 days after stopping
glycine, the brain glycine level may have returned to normal.
Further study is required to determine if elevated brain
glycine aﬀects regional cerebral blood ﬂow.
A.4. Brain Magnetic Resonance Imaging and Magnetic Res-
onance Spectroscopy. Magnetic resonance imaging (MRI)
studies were obtained at ages 15, 20, 25, and 27 and proton
spectroscopy (MRS) studies were obtained at ages 25 and
27. The MRI studies at ages 15, 20, 25, and 27 showed an
ovoid focus of increased proton density and T2 signal in
the right periatrial white matter. The long axis of this lesion
is perpendicular to the ventricle and measures less than 1
centimeter.
In the age-25 scan, the T2 hyperintensities were studied
more carefully. MR evaluation was performed with and
without contrast using the following sequences: T1 sagittal,
T1, T2, proton density, FLAIR and diﬀusion weighted axial
images. Following contrast administration, sagittal, coronal,
and postcontrast magnetization transfer axial sequences
were also obtained. Precontrast magnetization transfer axial
sequence was also performed as a control for contrast
enhancement on the postcontrast magnetization transfer
axial sequences. No abnormal contrast enhancement was
observed. The focus of high T2 signal was found to suppress
on ﬂair sequence and showed no signs of marginal gliosis
to suggest prior ischemia, inﬂammation, demyelination or
infection. Similar smaller lesions with increased T2 signal
are seen in the left centrum semiovale. Single voxel magnetic
resonance spectroscopy (MRS) was done on the ovoid lesion
and on a corresponding region on the left side. Values of N-
acetylaspartic acid, choline, and creatine were within normal
limits on both sides. Taking all of the evidence together, it
is most likely that the T2 hyperintensities are prominent
Virchow-Robin spaces. Signiﬁcant changes are not seen in
the 12 year period bracketed by the scans.
The age-25 MRI/MRS study demonstrated normal blood
volume throughout both cerebral hemispheres and the
posterior fossa. On the diﬀusion-weighted sequence, no
evidence of acute infarct was seen. Other brain scans
include a transcranial Doppler sonogram at age 25 (Day 85-
OP1(85)), which was unremarkable. A magnetic resonance
angiography scan with and without contrast was done at age
26 (Day 19-OP2(222). A normal scan was seen.
At age 27, an MRI/MRS study was done during a period
of high-dose glycine consumption (Day 50-OP7(818)). On
this occasion, 25 grams of glycine supplemented with 3
gramsofarginineweretakenoveraperiodofonehour[139].
Three hours after consumption of glycine + arginine, blood
was drawn for measurement of plasma glycine (∼1350μM)
and plasma ammonia (∼30μM). Approximately 1.25 hours
later, the proton magnetic resonance spectrum (3Tesla,
PRESS (point-resolved echo single-shot techninque), TE
(echo time) = 35msec) of Figure 2 was obtained. The voxel
was located in the right medial frontal region, the region of
greatest hypoperfusion on the SPECT scan of Figure 1.
Of special interest is a “shoulder” of signal at 3.55ppm
that is adjacent to the major myo-inositol peak at 3.61ppm.
This shoulder is expected to reﬂect contributions from theNeural Plasticity 21
glycine resonance at 3.55ppm and the minor myo-inositol
resonance at 3.52ppm. In prior studies with 1.5–2.0Tesla
scanners and short echo times, a clearly detectable 3.55ppm
shoulder has been seen only in conditions where there is a
known excess of glycine (e.g., nonketotic hyperglycinemia)
[121, 122]. More recent studies suggest that this is also the
case with 3Tesla scanners. For example, in an MRS study of
greymatterinahealthyindividual(3Tesla,TE=40msec),no
shoulder at 3.55ppm was seen [140]. Similarly, in a study of
the medial frontal cortex in an individual with OCD (3Tesla,
TE = 30msec), no shoulder at 3.55ppm was seen [141]. The
absence of 3.55ppm shoulders in these spectra of individuals
not taking glycine and the presence of such a shoulder in
O’s spectrum (3Tesla, TE = 35msec) are consistent with
an elevated glycine level arising from the elevated plasma
glycine that followed glycine consumption 4.25 hours before
the scan. However, deﬁnitive detection of elevated glycine
will require on-glycine and oﬀ-glycine measurements, and
monitoring of the expected metabolism of elevated levels to
baseline levels.
O’s 3Tesla spectrum is of also of interest in relation to
the prominent GLX peak at 2.02–2.5 ppm. An enlarged GLX
peak is consistent with an increased contribution from the
glutamine resonance at 2.45 ppm as a result of ammonia
production from glycine metabolism in the brain. Note that
plasma ammonia is unlikely to be an issue in this instance,
since its measured value ∼1.25 hours before MRS was well
within the normal reference range. A peak at 0.9–1.2 ppm is
also seen and is likely to be of lipid origin.
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